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ABSTRACT  
   
Exposure of blood plasma/serum (P/S) to thawed conditions, greater than -30°C, 
can produce biomolecular changes that misleadingly impact measurements of clinical 
markers within archived samples. Reported here is a low sample-volume, dilute-and-
shoot, intact protein mass spectrometric assay of albumin proteoforms called 
“ΔS-Cys-Albumin” that quantifies cumulative exposure of archived P/S samples to 
thawed conditions. The assay uses the fact that S-cysteinylation (oxidation) of albumin in 
P/S increases to a maximum value when exposed to temperatures greater than -30°C. The 
multi-reaction rate law that governs this albumin S-cysteinylation formation in P/S was 
determined and was shown to predict the rate of formation of S-cysteinylated albumin in 
P/S samples—a step that enables back-calculation of the time at which unknown P/S 
specimens have been exposed to room temperature. To emphasize the capability of this 
assay, a blind challenge demonstrated the ability of ΔS-Cys-Albumin to detect exposure 
of individual and grouped P/S samples to unfavorable storage conditions. The assay was 
also capable of detecting an anomaly in a case study of nominally pristine serum samples 
collected under NIH-sponsorship, demonstrating that empirical evidence is required to 
guarantee accurate knowledge of archived P/S biospecimen storage history.  
The ex vivo glycation of human serum albumin was also investigated showing that 
P/S samples stored above their freezing point leads to significant increases in glycated 
albumin. These increases were found to occur within hours at room temperature, and 
within days at -20 °C. These increases continued over a period of 1-2 weeks at room 
temperature and over 200 days at -20 °C, ultimately resulting in a doubling of glycated 
albumin in both healthy and diabetic patients. It was also shown that samples stored at 
  ii 
lower surface area-to-volume ratios or incubated under a nitrogen atmosphere 
experienced less rapid glucose adduction of albumin—suggesting a role for oxidative 
glycation in the ex vivo glycation of albumin. 
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CHAPTER 1 
INTRODUCTION 
1.1 The biological function, and importance of proteins 
Proteins are the macromolecules that accomplish most of the genetically 
instructed plans and tasks inside and outside of cells and tissues. Proteins vary in size 
from about 70 amino acids up to as large as ~30,000 amino acids. The primary sequence 
of amino acid residues enables specific functions of proteins through directing the folding 
of the native proteins into three-dimensional architectures. The sequence of the amino 
acid monomers found in proteins is encoded in the nucleotide triplet code of the DNA in 
every gene, this information is passed from DNA to protein through the messenger RNA 
pathway. The information pathway, DNA to RNA to protein, was discovered by 
molecular biologists in the 1960s (1, 2). This discovery showed how information stored 
in the stable DNA sequence of genes is transcribed into RNA molecules. RNA is then 
translated from nucleotide code to amino acid-based code in proteins, which are the 
major players that accomplish the functions of life. 
Scientists have recently discovered that the human proteome is vastly more 
complex than the human genome. It is estimated that the human genome comprises 
between 20,000 and 25,000 genes, the total number of proteins in the human proteome is 
estimated at over 1 million. These estimations demonstrate that multiple proteins can be 
encoded by a single gene. Genomic recombination, transcription initiation at alternative 
promoters, differential transcription termination, and alternative splicing of the transcript 
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are mechanisms that generate different RNA transcripts from a single gene leading to the 
diversity of the proteome. 
Proteins are polymers made up from 20 different standard (canonical) amino 
acids. Each amino acid consists of a carbon atom bonded to a carboxyl group (COO-), an 
amino group (NH3
+) and a distinctive side chain. The specific chemical properties of the 
different amino acid side chains determine the roles each amino acid will have in protein 
structure and function. The amino acids can be grouped into four broad categories 
according to the properties of their side chains (nonpolar, polar, basic, and acidic). The 
side chains of two amino acids, cysteine (Cys) and methionine (Met), are unique in that 
they contain sulfur atoms. Cys however contains a free sulfhydryl (SH) group, as will be 
discussed later, the sulfhydryl group of Cys plays an important role in protein structure 
because it allows the formation of disulfide bonds between the side chains of different 
Cys residues.     
1.2 Post Translational Modifications of Proteins 
The increase in complexity from the level of the genome to the proteome is 
further facilitated by protein post-translational modifications (PTMs). PTMs of proteins 
refers to the chemical change proteins may undergo after translation. PTMs play a key 
role in the proteome because they regulate activity, localization, and interaction with 
other cellular molecules such as proteins, nucleic acids, lipids and cofactors. Recent 
developments in mass-spectrometry (MS) methods have enabled the identification of 
thousands of PTM sites. Hundreds of diverse types of PTMs are currently known (3, 4). 
Most, if not all, proteins are modified extensively after their synthesis by specific 
cuts, proteolytic cleavages in the peptide chain, chemical modification of certain amino 
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acid residues, or by the addition of one or more non-amino acid prosthetic groups, such 
as sugar, lipid or phosphate residues. PTMs are important to the overall structure-function 
characteristics of proteins and extend the range of functions of the protein either by 
attaching biochemical functional groups (e.g., phosphate, acetate, or carbohydrates) or by 
making structural changes, such as protein oxidation (e.g., formation of disulfide bridges, 
sulfoxides) to the amino acids present in the protein (5-9). These modifications, in turn, 
effect the overall functional properties of proteins (10, 11).  
PTMs come in a wide variety of types and are mostly catalyzed by enzymes that 
recognize specific target sequences in specific proteins. The most common modifications 
are the specific cleavage of precursor proteins; formation of disulfide bonds; or covalent 
addition or removal of low-molecular-weight groups, thus leading to modifications such 
as acetylation, amidation, biotinylation, cysteinylation, deamidation, glutathionylation, 
glycation (nonenzymatic conjugation with carbohydrates), glycosylation (enzymatic 
conjugation with carbohydrates), hydroxylation, methylation, oxidation, phosphorylation, 
or sulfation. 
PTMs play a fundamental role in regulating the folding of proteins, their targeting 
to specific subcellular compartments, their interaction with ligands or other proteins, and 
their functional state, such as catalytic activity in the case of enzymes or the signaling 
function of proteins involved in signal transduction pathways. Some PTMs (e.g., 
phosphorylation) are readily reversible by the action of specific deconjugating enzymes. 
The relationship between modifying and demodifying enzymes allows for rapid and 
economical control of protein function. A similar control by protein degradation and de 
novo synthesis would take much longer time and cost much more bioenergy. 
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As mentioned earlier PTMs are typically mediated by enzymes, but there are 
several reported cases of protein modifications thought to occur via spontaneous 
chemical reactions. Although the regulation of enzymatic modifications is quite distinct 
from that of non-enzymatic modifications, the two processes are not mutually exclusive 
and, in some instances, can occur in parallel, as in the case of lysine (Lys) acetylation 
(12). Non-enzymatic PTMs can be viewed as the result of a reaction between a reactive 
metabolite and a nucleophilic or redox-sensitive amino acid side chain. The oxidation of 
Cys to sulfenic acid by hydrogen peroxide provides an example of this type of reaction. 
Variations in the concentration of hydrogen peroxide can be sensed by distinct Cys 
residues that are reactive toward this oxidant and located at an accessible site. A 
subsequent change in the redox environment can result in reduction of sulfenic acid 
moieties by antioxidants such as glutathione, and regeneration of free Cys (13). 
A protein of interest is the multifunctional plasma protein, human serum albumin, 
which is the most abundant plasma protein (about 60% of total protein content). It is a 
medium globular protein of 66k Da that accounts for both antioxidant functions, such as 
reactive oxygen species (ROS) scavenging, extracellular redox balance, and transport 
functions for many molecules. Among its 585 amino acids it contains 35 Cys residues, 34 
of which form structural disulfide bonds, leaving one free Cys (Cys34) that is prone to 
oxidation through disulfide-bond formation via exchange with free cystine (Cys-Cys) and 
oxidation of free Cys from the blood, resulting in S-cysteinylated (oxidized) albumin (S-
Cys-Alb)—both in vivo and ex vivo (14). Cys34 accounts for over 80% of the total free 
thiols (R-SH) in plasma and 70-90% of circulating albumin contains Cys34 in the 
reduced state (15), which is highly susceptible to oxidative PTM.  
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1.2.1 Cysteine Oxidation 
Oxidative PTM of Cys residues is an important mechanism that regulates protein 
structure and ultimately function. The unique properties of a Cys side chain permit a 
variety of oxidative PTMs, which potentially result in diverse regulatory effects (16). The 
side chain of a Cys residue contains a terminal thiol (R-SH) functional group. The sulfur 
atom at the core of the thiol is electron rich and its d-orbitals allow for multiple oxidation 
states (17, 18), which influences the formation of a varied range of oxidative PTMs. 
Thiol oxidation is among the most ubiquitous reactions in biology, playing key roles in 
protein folding, redox homeostasis, signal transduction, and the regulation of gene 
expression (19).  
Thiol oxidation leads to the formation of various reversible and irreversible 
products. Among the products of Cys oxidation, sulfenic acids and disulfides are of 
interest given the roles that they play in redox cycling and/or regulation of enzymes and 
transcription factors involved in cell signaling processes. One basic chemical reaction 
that is well understood is the oxidation of Cys to Cys-Cys. This oxidation occurs through 
a simple disulfide exchange (inter- or intra-molecular) mechanism or through a disulfide 
formation mechanism where, in the presence of oxygen and trace metals, two thiols can 
form a disulfide bond (13, 20). There are multiple routes in which Cys thiols can form 
disulfides as seen in Fig. 1.1. The simplest method is through a disulfide-based exchange 
forming intramolecular and intermolecular disulfides. However, free thiols (R-SH) can 
form thiolates (R-S-) through simple acid-base chemistry which can then either be 
oxidized by hydroperoxides in a two-electron oxidation process that yields sulfenic acid 
(R-S-OH) or a one-electron process that forms thiyl radicals (R-S•) through the reaction 
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of thiols with enzymes such as ribonucleotide reductase (21). Sulfenic acid can either 
react with free thiols to form disulfides or be further oxidized to sulfinic/sulfonic acids. 
The thiyl radicals can react directly with free thiols to form disulfides or react with 
molecular oxygen/superoxide to yield sulfinic acid. Ultimately, this process leads to the 
oxidation of susceptible proteins such as albumin. 
1.2.2 Protein Glycation  
 Human serum albumin can also be glycated in vivo and ex vivo. Glycation is a 
non-enzymatic process in which proteins react with reducing sugar molecules and may 
change the characteristics of the proteins. The reaction occurs between the α amino group 
of the N-terminal amino acid or the ε amino groups of Lys and the aldehyde or keto 
group of the reducing sugar (22). Sugars (e.g., glucose) can react with amino groups 
directly leading to protein glycation. However, sugars may also go through an 
autoxidative type reaction that makes the sugar molecule more reactive toward protein 
amino groups, which ultimately promotes excess protein glycation (23). The first step in 
this autoxidative type reaction is the formation of an unstable Schiff base, which 
rearranges to form a more stable Amadori product. The Amadori product can then react 
further to form irreversible cross-linked products called advanced glycation end products 
(AGEs) (Fig. 1.2).    
1.3 The Effects of Ex Vivo Protein modifications 
It has been previously shown that protein modifications (e.g., oxidation and 
glycation) occur ex vivo in blood plasma and serum (P/S) under common but suboptimal 
storage/handling conditions, which can potentially lead to false conclusions regarding 
physiological oxidative stress in clinical research (14, 24-26).  
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When plasma or serum (P/S) is exposed to air, the dissolved oxygen concentration 
[O2(aq)] can increase up to approximately 0.25 mM (27, 28)—an O2(aq) concentration 
that is much higher than that found in the P/S compartment of blood in vivo, this initiates 
the process of certain oxidative PTMs. Within proteins, such oxidative insults typically 
occur at the sulfur atoms of Cys and Met residues. Oxidative alteration of these amino 
acids changes the biochemical properties of affected proteins in a manner like amino acid 
substitution. This process may quite literally be considered unnatural amino acid 
substitution. Viewed in this manner, it is not surprising that even a minor alteration, such 
as oxidation of Met into Met sulfoxide, is an established means by which protein-protein 
binding interactions may be disrupted. Reviewing some of the literature available on this 
topic reveals that Met oxidation has been documented to disrupt a large variety of 
biomolecular interactions including Met oxidized (MetOx) antibody binding to protein 
A/G and Fc receptors (29-31), MetOx calmodulin binding to its receptor (32, 33), the 
activity of MetOx parathyroid hormone (34-37), MetOx antigenic peptide binding to the 
MHC and subsequent recognition by the T cell receptor (38), the binding of a MetOx C-
type natriuretic peptide analog to its receptor (39), and the binding of the MetOx prion 
protein (PrP) to antibodies against its Helix-3 region (40).  
When looking at how this could possibly affect the outcome of clinical research. 
Gaza-Bulseco et al. showed that when the methionine on a monoclonal antibody is 
oxidized, there is a decrease in the binding affinity between the antibody and the protein 
of interest. The study used ELISA and surface plasmon resonance, both of which rely on 
protein interaction, to show that the binding affinity between antibody and protein is 
disrupted by methionine oxidation. This oxidation-induced decrease in the binding 
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affinity led to a lower apparent abundance of the protein, ultimately resulting in an 
apparent quantitative loss of the protein being measured (29). Thus, it is evident that 
protein oxidation in improperly handled clinical samples should not be dismissed as an 
unimportant event that has no possible bearing on the outcome of clinical assays that rely 
on protein interactions. 
1.4 Storage and Handling of Plasma and Serum Samples 
There are many clinically important P/S biomolecules used as biomarkers that are 
unstable ex vivo, and susceptible to ex vivo modifications (13, 41-44). Ex vivo storage and 
handling conditions have the potential to impact measurements of these molecules as 
much or more than the in vivo conditions of interest (13, 32, 45, 46). Many biological 
samples, especially those used for long term research or archived for future research, are 
stored in freezers raising the question, “Have these samples been stored properly to give a 
correct assessment for a particular study?”  
There are many reasons in why researchers are interested in storing samples for 
long period of times, one of the main reasons is that samples are extremely valuable, both 
financially and scientifically. The cost, financially, that goes into the process of collecting 
samples is expensive, which leads primary investigators into wanting to get as much in 
return as they can out of their samples. One way in which they can recoup some of the 
initial cost of collecting samples is to sell the samples to other secondary investigators or 
receive grant subcontracts from other investigators. When this is done, not only does this 
help the primary investigator financially, but it also helps the entire scientific community 
by being able to address a separate scientific question beyond the ones of the primary 
study. This is a good thing but can create problems when the integrity of the samples 
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comes into question. Comprehensive and well-maintained biobanks are becoming 
prevalent to help mitigate some of these concerns. 
1.4.1 Biobanking 
Biobanks are repositories that assemble, store, and manage collections of human 
specimens and related data. Biobanks are one of the major sources used when 
investigators procure stored or archived samples. One of the first biobanks in the United 
States was the Armed Forces Institute of Pathology (AFIP). The AFIP was established in 
1862 as the Army Medical Museum and later evolved, over the span of a century, into a 
joint military-civilian organization. The AFIP has procured and developed, over the last 
150 years, a repository of samples from over 3 million clinical cases, 10 million tissue 
specimens, and 50 million paraffin blocks that cover the entire spectrum of human and 
animal disease (47). Currently there are more than 160 biobank repositories in the United 
States and many more throughout the world, all of which contain millions of stored 
samples (48). 
Biobanks have been around for many years in some form or another. However, 
recently there has been increased attention on the way that researchers and organizations 
manage them and the way in which samples are being stored. This increased attention has 
led to an increase in the number of biobanks (59% have been established since 2001) and 
in effect, the number of samples that are being stored has increased as well (49-51). 
Biobanks are useful in that studies don’t need comprehensive Institutional Review Board 
(IRB) or Institutional Ethics Committees (IEC) approvals for the use of biobanked 
samples, due to the fact this was performed during sample collection.  
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Academic and epidemiological research forms an important foundation of the 
need for biobanks. Biobanking facilities can range from large global-scale repositories for 
collaborative research to smaller stores employed by service industries, academic 
departments and pharmaceutical companies (52). There are also various purposes of 
biobanks, such as diagnostic, therapeutic, or research which all have different standard 
operating protocols (SOPs), meaning not all samples are stored the same way. Thus, the 
decision on what type, processing protocol, and volume of biospecimens to include in a 
biobank for specific purposes may affect all other downstream analyses and logistical 
processes.  
Biobanks in the United States have on average around 500,000 specimens stored 
at any given time, biobanks can range from very small (less than 100 specimens) to very 
large (more than 50 million) (49). Henderson et al. reports that around 75% of biobanks 
receive their specimens from direct contributions by individual donations, 57% of 
biobanks receive residual specimens that were previously acquired from hospitals and 
other clinical settings and 13% of biobanks receive specimens from research studies. 
Approximately, 76% of biobanks receive specimens that come primarily from individuals 
with some type of disease and approximately, 77% of biobanks store serum or plasma 
(49). With so many different samples being collected and the logistics that go into storage 
and handling, investigators need to be aware that sample integrity may be a major 
concern when it comes time to distribute these samples for future clinical research.  
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1.4.2 Plasma and Serum Integrity of Stored/Archived Samples 
Blood P/S proteins are not intrinsically stable. For example, pre-analytical sample 
handling and storage conditions can dramatically impact proteolytic enzyme activity and 
subsequent protein concentration measurements, potentially rendering assay results 
invalid. While acceptable pre-analytical handling and storage conditions are generally 
well defined for FDA-approved clinical protein assays, they cannot always be optimally 
pre-defined for clinical research studies where samples are to be archived indefinitely for 
future research. This creates a need for quality control tools (e.g., markers and assays) 
that allow for retrospective assessment of sample integrity (45, 46). Such tools are 
becoming more important as the practice of biobanking continues to rise worldwide. 
The varying quality of the existing biospecimens in biobanks has been identified 
as one of the major concerns inhibiting scientific progress (53-55). Oftentimes sample 
integrity is overlooked, to expand this point further, there are currently no universally 
accepted reference markers of biospecimen integrity. Identifying and standardizing 
quality control (QC) markers that are easy to monitor, represents an important objective 
of biobanking related research. This has created an urgent and growing demand to 
minimize ex vivo changes to P/S samples and to accurately identify those changes when 
they do occur (45). Most markers currently proposed for retrospective analysis of P/S 
specimen integrity are based on an apparent quantitative loss (or ‘paradoxical’ increase) 
in a particular target molecule without consideration of the molecular root cause (45). 
Preanalytical variables can introduce modifications, either systematically or 
randomly, that adversely affect results. When the result of a test deviates from that which 
is expected, the analytical integrity of the results is often questioned rather than the 
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preanalytical integrity of the samples. Ultimately, the test analysis can be perfect, but still 
the result could be inaccurate. Most errors in a clinical chemistry laboratory are due to 
preanalytical errors which can account for 32%-75% of laboratory errors (56-58). These 
errors can have a significant impact on laboratory results and it is imperative that 
laboratory personnel are able to spot these erroneous results, rather than falsely 
attributing them to an underlying medical cause. When these preanalytical errors are not 
accounted for in the clinical research settings it is not the patients that are impacted, but 
rather the scientific community. These errors mislead researchers into pursuing research 
based on incorrect results that have been published in the literature.  
Preanalytical variables can be grouped into three categories: sample collection, 
sample processing, and sample storage and handling. In both clinical and research 
settings, blood collection has the advantage of being minimally invasive. However, in 
clinical settings specimens are often quickly analyzed, whereas in research settings these 
samples can be stored anywhere from hours to months, possibly years, before they are 
analyzed, making sample collection protocols important to ensuring sample processing 
can be expedited and samples stored properly (59). As an example, there is an increased 
risk of hemolysis in P/S samples associated with the amount of time a tourniquet is in 
place (60), in other words, red blood cell lysis will introduce components into the P/S 
sample that are not representative of the in vivo condition, which may interfere with 
downstream analytical conclusions. Another factor to take into consideration during 
sample collection are the type of collection tubes. Each tube must be filled in a specific 
order to prevent cross contamination of blood additives within the collection tubes (61). 
One must also worry about how old the collection tubes are. The vacuum contained 
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within the tube determines how much blood will be collected to fill the tube completely. 
The closer to the expiration date, the weaker the vacuum may be within the tube, causing 
the tubes to not be fully filled. This may reduce the reproducibility of downstream 
analysis. 
 After collection, the manner in which specimens are processed plays a critical role 
in the quality of samples obtained. Centrifugation speeds, duration and temperature can 
affect the quality of the sample as speeds that are too fast, too long or not at the correct 
temperature will damage cell components, introducing an environment that may not 
represent the actual in vivo conditions, reducing the reliability and reproducibility of 
results between samples. Not only will the process of centrifugation affect the quality of 
samples, but also the time, or delay, for samples to be centrifuged. A delay in the 
separation of plasma and serum from whole blood has been shown to decrease the 
consistency of analytes, such as cytokines (62), even a delay in centrifugation as short as 
4 hours when samples are stored at 4 °C has an apparent effect on the concentration of 
different analytes that are found in plasma and serum (63).   
Laboratory staff are trained to pick up obvious problems in samples such as 
hemolysis or abnormal coagulation, but what about the problems that aren’t obvious or 
even visible? To illustrate this point, consider a cut apple that is left out on the table, 
there is an oxidation reaction that occurs and causes the apple to turn brown. However, if 
a P/S sample is left out there is no visible change, but it would be naïve to think that 
similar oxidative processes occurring in the apple would not occur in a P/S sample, the 
only difference being there is no visual change that will inform the analyst the sample has 
been mistreated. 
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SOP’s are in place to maximize reproducibility (decrease the amount of error) in 
biospecimen collection and processing. However, the preanalytical variable of storage 
and handling remains as the main source of error in clinical research carried out on P/S 
samples. After sample collection and processing, the way in which samples are stored 
and handled has a dramatic effect on the outcome of analysis. This is seen in multiple 
unstable analytes that are of clinical interest in P/S (64-67).  
There are many ways in which samples can be stored after collection and 
processing; the best way is to have the P/S samples directly placed in a -80 °C freezer. 
However, not all collection sites may have a -80 °C freezer available for storage of 
samples leading to samples being stored at -20 °C or 4 °C for a short time. Whether it is 
overnight or for a couple days, the concern that the first collected sample may not be as 
“fresh” as the last sample collected becomes a valid question to contemplate. Another 
handling condition to consider is the transport of samples, whether it is going from across 
the hall or across the country, samples need to stay frozen. Samples are typically shipped 
with dry ice to keep them frozen, but delays (e.g., rerouted or canceled flights, delays in 
delivery) could possibly lead to samples thawing partially or completely. These are 
conditions that are sometimes uncontrollable and are not always documented.  
Many preliminary studies have suggested that PTMs of albumin (e.g., oxidation 
and glycation) are promising markers to evaluate the progression of oxidative stress-
related diseases, (68-70), though no definitive marker has been established. An example 
on how these suggested PTMs might be misrepresented is to look at the properties of 
stored albumin. A recent study has shown that albumin that is not completely frozen will 
have an increase in the amount of oxidation present (14). Consider a group of samples 
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where half of the samples were stored properly, and the other half were delayed in 
transport allowing them to partially thaw. If these studies, that suggest the use of albumin 
PTMs as markers of oxidative stress, were to use the group of samples just described, 
they may unknowingly attribute the increase in albumin oxidation/glycation to an 
oxidative stress-related disease, even though the increase comes from the preanalytical 
variable of storage and handling. In conclusion, suboptimal storage and handling 
conditions can potentially lead to false conclusions regarding physiological oxidative 
stress (14). Preanalytical variables, albeit seemingly minor, can impact the success of an 
assay or study.   
As mentioned, S-Cys-Alb has been previously identified as a protein-
representative oxidative molecular modification that results from poor sample storage and 
handling (14). To utilize this known oxidation as a biospecimen integrity marker, a 
simple, low sample consumption, high-throughput method that directly measures the 
molecular modification has been developed (14). The goal of this research is to develop a 
model that will allow for subsequent prediction of the rate and extent to which oxidative 
S-Cys-Alb occurs ex vivo, when samples are exposed to thawed conditions (e.g., 
temperatures > -30 °C). Then using this information, develop an assay to measure the 
integrity of long-term stored P/S samples rapidly and efficiently.  
P/S samples that are not stored properly may have many modifications occur ex 
vivo that will change or alter the results of research studies (45). As has been shown 
previously and will be shown further in this work, protein PTMs (e.g., oxidation and 
glycation) may affect the quality and outcome of stored samples, leading to false or 
misleading results in clinical research studies. It is imperative that the samples collected 
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and stored today are suitable for the future. The work described below will help ensure 
that future researchers can have confidence in the quality of their plasma and serum 
samples and ultimately, the quality of their research.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.1. Thiol/Disulfide Redox Reaction Pathway. Thiol-disulfide exchange (1). 
Thiol acid-base behavior (2). One-electron oxidation of thiolates to thiyl radicals (3). 
Thiyl radicals can react with molecular oxygen/superoxide or other thiols, yielding 
sulfinic acid and disulfides as final products (4 and 5).  Thiolates can react through a 
two-electron oxidation process yielding sulfenic acid (6). Sulfenic acid can be further 
oxidized to sulfinic and sulfonic acids (7). Inter- and intramolecular disulfides are 
formed from the reaction of sulfenic acid with other thiols (8). 
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CHAPTER 2 
KINETIC RATE MODEL OF EX VIVO S-CYSTEINYLATION (OXIDATION) OF 
HUMAN SERUM ALBUMIN 
2.1 Introduction 
The rate of reaction is important to predict how quickly a reaction mixture 
approaches equilibrium and helps lead to an understanding of the mechanisms behind the 
reaction. Reactions can be broken down into a sequence of elementary steps and then 
analyzed to determine the rates of each of these steps. Such studies lead to an empirical 
rate law that relates the reaction rate to the concentrations of reactants, products, and 
intermediates at any point in time.  
When it is possible to measure the reaction that is occurring, there are two 
methods in which to determine the rate law, either by the isolation method or the method 
of initial rates. The isolation method uses the concept of increasing, in excess, all the 
reactants present in the reaction except for one, in this case all reactants except for the 
one being measured can be considered constant. This will produce the appearance of a 
first-order rate law, or in other words a pseudo first-order rate law, which is much easier 
to analyze and identify the rate law regarding the one reactant not in excess. The 
dependence of the rate on the concentration of each of the reactants may be found by 
isolating them in turn (by having all the other reactants present in large excess), and so 
constructing a picture of the overall rate law.  
In the method of initial rates, the initial rate is measured at the beginning of the 
reaction for several different initial concentrations of each reactant. For a series of initial 
concentrations, a plot of the logarithms of the initial rates against the logarithms of the 
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initial concentrations of the reactant should produce a straight line, with the slope of the 
line equal to the order of reaction. The rate constants for the given rate law can then be 
determined by using non-linear regression, using all initial rates and concentrations of the 
reactants in the calculation. Once the rate constants and the order of reaction have been 
determined the overall rate law can then be solved by integrating the reaction equations, 
using differential equations, that will give the concentration as a function of time. An 
advantage of using the method of initial rates compared to the isolation method is it does 
not require the assumption that a pseudo first order reaction has been achieved.  
Recent studies have shown that under thawed conditions albumin oxidation in P/S 
samples increases in a regular pattern (14). When considering the reactions that govern 
this albumin oxidation, shown in Reactions 1 and 2, a simple disulfide exchange 
mechanism is observed, where AlbSH is the native reduced form of albumin, Cys-Cys is 
cystine, SCysAlb is S-cysteinylated albumin, and Cys is cysteine. With the determination 
of these reactions it is possible to use the method of initial rates to determine the rate 
constants and order of reaction for the oxidation and reduction of albumin, and ultimately 
determine the overall rate law of the reaction. With the determination of the overall rate 
law a predictive kinetic rate model for albumin oxidation can be established. 
 
An established rate law of this reaction would allow the measurement of albumin 
oxidation at any given time to be linked to the amount of time a P/S sample has spent at 
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room temperature like conditions. This would represent an unprecedented achievement in 
biospecimen science and would lay the groundwork for linking any clinical biomarker of 
interest to albumin oxidation without necessarily having to measure the two markers 
simultaneously in the same sample. 
Shown here is the use of the method of initial rates combined with intact protein 
mass spectrometry to determine the kinetic rate law for the ex vivo oxidation of human 
serum albumin at room temperature. The determination of this rate law makes it possible 
to model and predict the ex vivo oxidation of human serum albumin and facilitates its use 
as a predictive marker in clinical biospecimen integrity. 
2.2 Materials and Methods 
2.2.1 Materials and Reagents 
Highly purified human serum albumin (Cat. No. A3782), L-cysteine (C7352), 
trifluoroacetic acid (TFA, 299537), L-Cystine (30200), L-Cystine dihydrochloride 
(C2526), L-Cysteine-2,3,3,-D3 (701424), Amicon Ultra-4 centrifugal filter, MWCO = 50 
kDa (Z740191), ammonium hydroxide (320145), ammonium bicarbonate (A6141), 
sodium sulfate (S9627), deferoxamine mesylate salt (D9533), HEPES (H3375) and NaCl 
(S7653) for preparation of HEPES-buffered saline solution (HBS buffer) were purchased 
from Sigma-Aldrich (St. Louis, MO). LC-MS grade Acetonitrile (TS-51101), LC-MS 
grade water (TS-51140), hydrochloric acid (50-878-166), Pierce BCA protein assay kit 
(23227), and methanol (A456) were purchased from ThermoFisher Scientific (Waltham, 
MA). Chelex 100 resin (1421253) was purchased from Bio-Rad Laboratories (Hercules, 
CA). SPE cartridges (SPE-P0005-03BB) purchased from Silicycle (Quebec, Canada). L-
Cystine-3,3,3’,3’-D4 (DLM-9812-PK) was purchased from Cambridge Isotope 
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Laboratories, Inc. (Andover, MA). N-Methyl-N-Trimethylsilyl Trifluoroacetamide 
(MSTFA) (24589-78-4) was purchased from Regis Technologies (Morten Grove, IL). All 
non-LC-MS solvents were of HPLC grade. 
Section 2.2.2 Plasma and Serum Samples 
Fasting EDTA plasma and serum samples were collected from healthy volunteers, 
via venipuncture, under IRB approval at Arizona State University. The samples were 
collected according to the National Institute of Health’s (NIH) Early Detection Research 
Network blood collection SOPs (71, 72). Within 35 minutes of collection, plasma 
samples were processed, aliquoted, and placed in -80 °C freezer; serum samples were 
placed at -80 °C within 95 minutes of collection. One or more of these P/S specimens 
were used for all experiments described below. Unless otherwise noted, aliquot volumes 
were 50 µL. 
2.2.3 Quantitative Model Development  
 The rate law for formation of S-cysteinylated or oxidized albumin (S-Cys-Alb) in 
the P/S environment is governed by the chemical reactions listed in Reactions 1 and 2. 
The rate law for Reaction 2 has been previously determined by Kachur et al. (20). Thus in 
order to obtain a complete combined rate law for formation of S-Cys-Alb, the rate laws 
for the forward and reverse reactions described in Reaction 1 were determined using the 
method of initial rates (73). Briefly, this approach entailed measuring the initial rate of 
the forward (and, separately, reverse) reaction by plotting S-Cys-Alb (or the reduced 
form of albumin (AlbSH)) concentration in molar units (M) vs. time (s). The initial phase 
of these plots was linear. From this initial linear phase, the slope was obtained and 
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recorded as the initial rate (vo). This process was repeated for multiple starting 
concentrations of reactants in which none of the products were initially present. 
This latter requirement made it necessary to create and isolate AlbSH in which no 
S-Cys-Alb was present and, for the reverse reaction, S-Cys-Alb in which essentially no 
AlbSH was present. Pure AlbSH was prepared starting with a 1 mM concentration of 
commercially prepared albumin in HBS buffer (pH 7.4). The sample was aliquoted into 
500 µL volumes and mixed with 300 µL of 10 mM Cys, followed by incubation for 1 
hour at room temperature. After the incubation period, 1 µL of sample was diluted in 600 
µL of 0.1% TFA and analyzed to verify complete reduction of albumin. The aliquots 
were then split into 200 µL aliquots in Amicon Ultra-4 centrifugal spin filters (MWCO 
50K). Each sample had 4 mL of HBS buffer added and then was centrifuged for 10 
minutes at 4,000 x g to a final volume of approximately 200 µL, this process was 
repeated 7 times, facilitating Cys removal and protein concentration. All aliqouts were 
then combined and albumin concentration was determined with a BCA protein assay, 
following the manufacturer’s protocol. To verify that no structural disulfide bonds were 
reduced and only the free Cys residue (Cys34) was reduced, 5 µL of AlbSH was 
incubated with 5 µL of 50 mM maleimide in ammonium acetate buffer (pH 5). This was 
incubated at 50 °C for 15 minutes and then 1 µL of sample was mixed with 500 µL of 
0.1% TFA and analyzed by LCMS (Fig. 2.1). Pure S-Cys-Alb was obtained by following 
the same protocol but instead incubating 0.5 mM commercially prepared albumin with 1 
mM Cys-Cys. All samples were stored at -80 °C until further analysis. 
To eliminate interference from Reaction 2 during the rate law determinations, 
trace quantities of copper and other transition metals were minimized by pre-treating all 
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buffers with Chelex 100 resin per the manufacturer’s batch-wise instructions. 
Desferrioxamine (0.2 mM) was also added to the buffers employed in rate law 
determinations. To determine initial rates, pure AlbSH at concentrations ranging from 30-
60 µM or pure S-Cys-Alb (30-90 µM) were incubated with free Cys-Cys or Cys (300-900 
µM) at 23 °C, respectively (Tables 2.1 and 2.2). A control sample with no added Cys-Cys 
or Cys was also prepared to ensure that no artifactual oxidation or reduction occurred. 
Time courses for albumin oxidation and reduction were acquired by diluting 0.5 µL of a 
sample into 0.1% TFA to a final concentration of 1 µM albumin at various time points, 
which was then analyzed by LC-MS to provide time point concentrations of S-Cys-Alb 
and AlbSH. Time points were taken more frequently during the initial linear portion 
which yielded a slope that was used to determine the initial rate of reaction for each of 
the varying concentrations (Tables 2.1 and 2.2). The method of initial rates was then used 
to determine the reaction orders and rate constants for the disulfide-exchange oxidation 
and reduction of albumin (73). Slopes of log vo vs. log reactant concentration (at several 
concentrations of the second reactant) were used to determine reaction orders and non-
linear regression of the entire forward-reaction dataset and reverse reaction dataset was 
employed to determine the forward and reverse rate constants, respectively.  
2.2.4 Quantitative Model Verification 
Immediately following collection, matched serum and K2EDTA plasma from a 
healthy donor were each split into two 95-µL portions: One portion was spiked with Cys 
and Cys-Cys (in 5 µL of HBS buffer, pH 7.4) to increase the concentration of Cys by 12 
µM and the concentration of Cys-Cys by 62 µM; the second portion was diluted by the 
same amount of buffer but without added Cys or Cys-Cys. These specimens were then 
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incubated at 23 °C for 4 days, with numerous measurements of S-Cys-Alb collected 
initially and then at least once a day after Day 1. The data were then fit with the 
predictive model (using Wolfram Mathematica 10.2 or MatLab 2016), using the 
empirically determined initial concentrations of all species, determined as follows. 
2.2.4.1 Measurement of Initial Reactant/Product Concentrations 
Fresh aliquots of matched P/S samples were sent to ARUP Laboratories to 
determine concentrations of albumin (total), free copper and total copper. Initial fractions 
of S-Cys-Alb and AlbSH were determined using the S-Cys-Alb assay described above. 
These fractions were then converted to actual concentrations by multiplying by the total 
albumin concentration. 
Cys-Cys concentration was determined from quadruplicate aliquots of serum and, 
separately, plasma using solid phase extraction (SPE) and gas chromatography-mass 
spectrometry (GC-MS) using procedures adapted from (74-76). Calibration curve 
samples were prepared in 40 mg/ml albumin in HBS buffer (pH 7.4) with the addition of 
0, 15, 30, 45, 60, or 90 µM of Cys-Cys. Three microliters of 2 mM Cys-Cys-d4 internal 
standard in 1 M ammonium hydroxide and 1 M ammonium bicarbonate (pH 9.4) were 
combined with 96.5 µL of P/S and calibration curve samples, followed by 0.5 µL of 1 
mM Cys-d3 internal standard in 1 M ammonium hydroxide and 1 M ammonium 
bicarbonate (pH 9.4). Proteins were then immediately precipitated by first adding 200 µL 
of acetonitrile and then 200 µL of 0.2 M HCl which lowered the sample pH, minimizing 
disulfide exchange reactions. Samples were incubated on ice for 30 minutes and then 
centrifuged for 2 minutes at 13,000xg to remove protein precipitate. Sample supernatant 
was then stored on ice until ready for cation exchange SPE. The SPE cartridges were 
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conditioned with 2 mL acetonitrile and then equilibrated with 2 mL of 0.1 M HCl. The 
entire sample was then loaded onto the cartridge and washed with 2 mL methanol. 
Samples were then eluted with 2 mL of 5% ammonium hydroxide in methanol into 
silanized glass test tubes and then dried using a Savant SC250EXP SpeedVac 
Concentrator. After samples were dry, 50 µL of acetonitrile and 50 µL of N-methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA) were added and then incubated for 30 
minutes at 85 °C. Samples were then loaded into GC-MS autosampler vials and injected 
onto the GC-MS. 
2.2.4.2 GC-MS 
GC-MS analysis was carried out on an Agilent Model A7890 gas chromatograph 
(equipped with a CTC PAL autosampler) coupled to a Waters GCT (time-of-flight) mass 
spectrometer. One microliter of the sample was injected in split mode onto an Agilent 
split-mode liner that contained a small plug of silanized glass wool. The injector 
temperature was set at 280 °C and the split ratio was 5:1. The carrier gas was regulated in 
constant flow mode at 0.8 mL/min. The capillary column was a 30-m fused silica DB-
5MS with a 0.25 µM film thickness and 0.250 mm inner diameter. The temperature 
program was started at 100 °C with initial holding for 1 minute and was increased at the 
rate of 10 °C/min to 300 °C and held for 3 minutes. The temperature was then increased 
30 °C/min to 325 °C, with final holding of 3 minutes. The temperature of the transfer line 
to the MS was 280 °C.  Mass spectra were obtained by standard (70 eV) electron 
ionization scanning from m/z 40 to 800 at a spectral accumulation rate of 0.09 
seconds/spectrum. 
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2.2.4.3 Data Analysis GC-MS 
Quantification was done by integrating summed extracted ion chromatogram 
(XIC) peak areas, using QuanLynx software. The peaks were integrated automatically 
and verified manually. The extracted ions (± 0.15 m/z units) used for quantification were: 
Cys-Cys (m/z 411.1 and 232.1), Cys-Cys-d4 (m/z 415.1 and 234.1), Cys (m/z 220.1, 
232.1, and 322.1), Cys-d2 (which results from reduction of Cys-Cys-d4 during 
derivatization as described below; m/z 222.1, 234.1, and 324.1) and Cys-d3 (m/z 223.1, 
235.1, and 325.1). All summed XIC peak integrals were exported to a spreadsheet for 
further analysis. 
Cys-Cys is partially reduced to Cys during the derivatization step that is necessary 
to facilitate analysis by GC-MS. As such, Cys ions were used in the quantification of 
Cys-Cys. However, to use Cys in this quantification scheme it was necessary to subtract 
out any signal that was due to the endogenous Cys. This was done by spiking in 5 µM 
Cys-d3 into each sample, which is equivalent to the concentration of endogenous Cys in 
P/S samples (as explained in the next paragraph and illustrated in Fig. 2.2). The 
magnitude of the summed XIC areas from Cys-d3 was then assumed to represent the 
magnitude of the summed XIC areas from endogenous Cys. Thus, the total area of the 
summed XICs from Cys-d3 was subtracted from the summed XIC areas of endogenous 
Cys. All residual summed XIC peak area from Cys ions was then considered to be 
derived from Cys-Cys. Prior to making this calculation, however, isotopic overlap 
between natural forms of Cys ions and their d2-labeled internal standard counterparts was 
corrected for based on the known isotopic distribution of each fragment ion employed for 
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quantification. This isotope correction procedure was analogous to that which has 
previously been employed and widely used elsewhere (77, 78). 
Given the initial concentrations of AlbSH, S-Cys-Alb, free and total copper, and 
Cys-Cys determined above, all rate law models with initial Cys concentrations anywhere 
within the physiologically observed range (79, 80) revealed that by the time plasma and 
serum were separated from whole blood, the concentration of Cys in P/S had equilibrated 
to a steady state concentration of ~ 5 μM (Fig. 2.2). Given this information and the fact 
that, relative to Cys-Cys, Cys contributes ≤ 5% of the total Cys equivalents in P/S, an 
initial Cys concentration of 5 μM was assumed in all kinetic models. 
2.2.5 Data Analysis LC-MS 
As previously described (14), approximately 1 minute of recorded spectra were 
averaged across the chromatographic peak apex of albumin. The electrospray ionization 
charge-state envelope was deconvoluted with Bruker DataAnalysis v3.4 software to a 
mass range of 1000 Da on either side of any identified peak. Deconvoluted spectra were 
baseline subtracted, and all peak heights were calculated, tabulated and exported to a 
spreadsheet for further analysis. Peak heights were used for quantification as opposed to 
peak areas, because of the lack of baseline resolution for some of the peaks. 
2.2.6 LC-ESI-MS 
 Relative quantification of intact albumin proteoforms was done by liquid 
chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) on a Dionex 
Ultimate 3000 HPLC equipped with a 1:100 flow splitter connected to a Bruker maXis 
4G quadrupole-time-of-flight (Q-TOF) mass spectrometer. A trap-and-elute form of LC-
MS was carried out in which 5 µL of sample was loaded via a loading pump at 10 μl/min 
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in 80% water containing 0.1% formic acid (Solvent A) / 20% acetonitrile (Solvent B) 
onto an Optimize Technologies protein captrap configured for uni-directional flow on a 
10-port diverter valve. The trap was then rinsed at this solvent composition with the 
HPLC loading pump at 10 µl/min for 3 minutes. The flow over the captrap was then 
switched to the micro pump, which was set at a flow rate of 3 µL/min and composition of 
65/35 A/B. This composition was held until 4.5 min. From 4.5-4.6 min. the composition 
was ramped to 55/45 A/B then held.  From 7.5-7.6 min. the composition was ramped to 
20/80 A/B then held. Then from 9.4-9.5 min. the composition was ramped back to 65/35 
A/B in preparation for the next injection. Following the valve switch at 3 minutes, the 
captrap eluate was directed to the mass spectrometer operating in positive ion, TOF-only 
mode, acquiring spectra in the m/z range of 300 to 3000. ESI settings for the Agilent 
G1385A capillary microflow nebulizer ion source were as follows: End Plate Offset -500 
V, Capillary -4500 V, Nebulizer nitrogen 3 Bar, Dry Gas nitrogen 3.0 L/min at 225°C. 
Data were acquired in profile mode at a digitizer sampling rate of 4 GHz. Spectra rate 
control was by summation at 1 Hz.  
2.3 Results 
2.3.1 Rate Law Determination of Ex Vivo Formation of S-Cys-Alb  
The major reactions that govern the ex vivo formation of S-Cys-Alb in P/S 
include:  
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Where AlbSH is the native reduced form of albumin, Cys-Cys is cystine, SCysAlb is S-
cysteinylated albumin, and Cys is cysteine.  
With the average initial starting concentrations of each reactant and product in P/S 
known and with the knowledge of the rate law governing the formation of S-Cys-Alb, it 
may be possible, in theory, to provide an estimate of the time spent by P/S samples at the 
temperature in which the rate law was determined. The rate law (including k3) for 
Reaction 2 was previously determined by Kachur et al. (20); the forward and reverse 
reaction rate laws for Reaction 1 were determined here at 23 °C. 
Reaction 1 is initially linear in both the forward and reverse directions (Fig. 2.3). 
Thus in order to be able to model a simultaneous system of chemical reactions comprised 
of Reactions 1 and 2, the forward and reverse rate laws for Reaction 1 were determined 
using the method of initial rates (73). To obtain albumin in fully reduced or fully oxidized 
form, high purity human serum albumin was fully reduced with Cys or fully oxidized 
with Cys-Cys, then spin-filtered to purify and concentrate the protein. Verification of 
complete reduction and oxidation was carried out by LC-MS of the intact protein 
following alkylation with maleimide to verify that no structural disulfide bonds were 
reduced (Fig. 2.1). Starting conditions for all incubations employed to determine the 
forward and reverse rate laws for Reaction 1 are provided in Tables 2.1 and 2.2, 
respectively. The slopes of plots of log vo (initial rate) vs. log [reactant concentration] 
(for several different co-reactant concentrations) revealed that the reaction order for all 
species in Reaction 1 was 1 (Fig. 2.4). Subsequently, the data in Table 2.1 were fit to the 
equation: 
vo = k1[AlbSH][Cys-Cys]  (3) 
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(where vo is the initial reaction rate in M/s) and non-linear regression was used to 
determine that k1 = 0.095 ± 0.017 M
-1 s-1. Likewise, the data in Table 2.2 were fit to the 
equation: 
vo = k2[SCysAlb][Cys]  (4) 
 
and non-linear regression was used to determine that k2 = 3.37 ± 0.44 M
-1 s-1. Given that 
k1 and k2 were determined at 23 °C, their values are consistent with the values of 0.6 ± 0.1 
M-1 s-1 and 6.6 ± 0.4 M-1 s-1 , respectively, that were just recently determined by Bocedi et 
al. at 37 °C (81). 
Once the forward and reverse rate laws for Reaction 1 had been determined, a 
series of differential equations that simultaneously consider Reactions 1 and 2 and their 
respective rate laws were assembled: 
 
In Equations 5-8, [Cu(II)] is the total concentration of copper (which stays constant), and 
Ky and Kz represent the first and second equilibrium dissociation constants pertaining to 
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Cys complexation of Cu(II) that are involved in the copper-catalyzed oxidation of Cys to 
Cys-Cys at pH 7.4 as described by Kachur et al. (20). Equations 5-8 cannot be solved 
explicitly, but numerical solutions at any point in time can be obtained once all constants 
and starting concentrations are supplied. 
2.3.2 Quantitative Model Verification in Serum and Plasma 
To evaluate the ability of the combined rate law model (Equations 5-8) to predict 
formation of S-Cys-Alb in actual plasma and serum, matched plasma and serum were 
collected from a healthy donor. Serum was collected into trace metal-free tubes to 
facilitate quantification of copper. Initial concentrations of S-Cys-Alb, AlbSH, Cys-Cys 
and free and total copper for use in the predictive model were made as described in 
Materials and Methods. Measurement of Cys was deemed unnecessary because according 
to the model, by the time serum or plasma are processed from whole blood the 
concentration of Cys drops to a steady state at about 5 µM—regardless of whether or not 
the initial concentration starts at the low or high end of physiological Cys concentrations 
observed in human plasma (Fig. 2.2)—and which, in terms of Cys equivalents, is within 
the error of Cys-Cys quantification.  
Immediately following collection serum and plasma were each split into two 
portions: One portion was spiked with Cys and Cys-Cys (in a minimal volume of HBS 
buffer, pH 7.4) to increase the concentration of Cys by 12 µM and the concentration of 
Cys-Cys by 62 µM; the second portion was left unmodified. A 100-µL aliquot of each 
specimen in a closed 1.5-mL snap-cap tube was then incubated at 23 °C for 4 days on a 
rotating vortex mixer (200 RPM), with numerous measurements of S-Cys-Alb collected 
initially and then at least once a day after Day 1. The data were then fit with the 
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predictive model, using the empirically determined initial concentrations of all species 
along with rate and equilibrium constants pertinent to the model, determined as described 
above (k1 and k2; Reaction 1 at 23 °C) or as previously determined (k3, Ky and Kz; 
Reaction 2 at 37 °C (20)) (Fig. 2.5).  To best approximate the latter three parameters at 
the actual temperature of the experiment (23 °C), a value of -50 kJ/mol was estimated as 
the enthalpy of reaction per Cys ligand binding to Cu(II) based on the known enthalpy of 
Cys binding to other divalent cations (82) (binding to Cu(II) is unknown). Integration of 
the van’t Hoff equation provides the following formula to estimate the change in an 
equilibrium association constant (K) with temperature (T) given the estimated change in 
enthalpy (ΔH°) (83): 
ln 𝐾2 = ln 𝐾1 −  
𝛥𝐻°
𝑅
(
1
𝑇2
−  
1
𝑇1
)   (9) 
where R is the ideal gas constant. Application of this formula to Ky and Kz resulted in a 
2.5-fold decrease in each value to 2.0 x 10-6 M and 3.5 x 10-4 M, respectively. The same 
factor was applied to estimate k3 as 0.13 s
-1 as well—a factor in the middle of the range of 
the fold-change expected for a 14 °C decrease in temperature (73)1.  All plasma copper 
was assumed to be catalytically available and half of serum copper (95% of which is 
bound to ceruloplasmin (85)) was assumed to be catalytically available since only about 
                                                 
1 In a simple system consisting of only buffer, Cu2+, and Cys, Reaction 2 exhibits two different kinetics phases—the 
first of which is faster and runs until the molar concentration of Cys is equal to that of Cu2+.   (20. Kachur, A. V., 
Koch, C. J., and Biaglow, J. E. (1999) Mechanism of copper-catalyzed autoxidation of cysteine. Free Radic Res 31, 23-
34). In the absence of a second co-reaction (i.e., Reaction 1) that generates fresh free thiol-containing Cys, all Cys is 
then bound to copper; hydrogen peroxide then accumulates in the absence of free Cys and subsequently drives the 
second reaction phase, the rate constant for which, at 37 °C, is 4.25-fold lower than the rate constant of the first phase.     
In P/S, Reaction 1 continually generates fresh Cys; moreover, the catalase concentration in P/S is about 50 U/mL     
(84. Goth, L. (1991) A simple method for determination of serum catalase activity and revision of reference 
range. Clin Chim Acta 196, 143-151)—a quantity sufficient to prevent accumulation of hydrogen peroxide and 
therefore the second reaction phase)—as such, only the rate constant for phase 1 of Reaction 2 was considered in the 
models presented here. 
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40% of ceruloplasmin-bound copper resides in the Cu(II) oxidation state (86). Models in 
which only free copper, only the ~5% of copper not bound to ceruloplasmin, or all copper 
in serum were assumed to be catalytically available show that a major portion of bound 
copper must be catalytically available (Fig. 2.6). Additional models in which Ky, Kz, and 
k3 are run at their 37 °C-values and 10-fold below these values are also provided for 
illustrative purposes, see Appendix A. 
RMSD fit (expressed as %CV) for unfortified serum was 6.1% and that for 
unfortified K2EDTA plasma was 6.3% (Fig. 2.5). The observed S-Cys-Alb trajectory in 
the matched serum and plasma samples, that were fortified with 62 µM Cys-Cys and 12 
µM Cys, however, did not match the model predictions (Fig. 2.5). Considering that the 
rate law established for Reaction 2 (20) assumed that dissolved oxygen concentration 
[O2(aq)] would not be rate limiting (i.e., did not take it into account)—in conjunction 
with the fact that dissolved oxygen demand would be substantially higher in P/S fortified 
with extra Cys-Cys and Cys—it was reasoned that the observed lower-than-predicted S-
Cys-Alb formation rate may have been due to [O2(aq)] becoming rate limiting at the 
unnaturally high Cys-Cys and Cys concentrations fortified into P/S.  Simulation results 
from a more complex (but currently speculative) model than that provided by Equations 
5-8 support this explanation, see Appendix B.  
To evaluate the practical effect on S-Cys-Alb of processing plasma normally then 
storing samples under an inert atmosphere in sealed vials, parallel incubations of freshly 
collected plasma in air and under a nitrogen atmosphere (using a Spilfyter “Hands-in-a-
Bag” artificial atmospheric chamber) were conducted. Initial rates of S-Cys-Alb 
formation under the two atmospheres were nearly identical, but eventually deviated and 
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resulted in a modestly lower maximum concentration of S-Cys-Alb in the sample 
incubated under nitrogen (Fig. 2.7). These experimental results compare favorably with 
the [O2(aq)]-dependent model in which a modest concentration of O2(aq) (70 µM) is 
assumed at the outset but no further O2 can enter the unfortified sample over time (see 
Appendix B, part B, panel n).  
2.4 Discussion 
The chemical reactions that contribute to S-Cys-Alb formation in P/S ex vivo are 
known (Reactions 1 and 2).  This made it possible to actually determine rate laws and 
develop a mathematical model to facilitate: First, predict how albumin oxidation will 
behave across a wide range of reactant and product starting concentrations and second, 
back-calculate the approximate time at which an “average” P/S specimen has been 
exposed to the temperature(s) at which the rate law has been determined. 
The initial rate law model developed here assumes that the concentration of 
dissolved oxygen, [O2(aq)], in P/S is not rate limiting. This appeared to hold true in 
samples that contained a physiologically normal concentration of Cys and Cys-Cys (Fig. 
2.5). Two observations, however, suggested that the [O2(aq)] in P/S was very close to 
becoming rate limiting: First, storage of unfortified plasma under nitrogen after initial 
processing was found to limit the overall formation of S-Cys-Alb (Fig. 2.7). And second, 
the rate at which S-Cys-Alb forms in unfortified P/S samples was accurately predicted by 
the model that does not take [O2(aq)] into account while the rate at which S-Cys-Alb 
forms in P/S samples fortified with extra Cys and Cys-Cys is significantly overestimated 
by this model (Fig. 2.5). Yet the rate at which S-Cys-Alb forms in both unfortified and 
fortified P/S can be predicted using a model that takes [O2(aq)] into account (Appendix 
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B). Thus, the present model based on Equations 5-8 should only be employed under two 
conditions: First, when P/S samples are known to have been stored under air, and second, 
in patient populations without kidney disease requiring hemodialysis.  
  The rate and equilibrium constants associated with Reaction 2 were determined 
for Cu(II) in a 40 mM sodium phosphate buffer (20)—a solution wherein the copper ions 
would be complexed to the various protonated forms of phosphate ions present. In serum, 
however, 95% of copper is bound to ceruloplasmin (85) and in K2EDTA plasma 
essentially all of the copper is bound to the ~5 mM EDTA present. As such, the values of 
k3, Ky and Kz used here—while appear to be reasonably accurate empirically (Fig. 2.5; 
Appendix A)—are not necessarily accurate representations of these values as they exist in 
actual P/S. Transition metals besides copper—most prominently iron—may also play 
some role in catalyzing Reaction 2 in P/S. “Free” or non-transferrin bound iron is 
typically in the nM range in serum (87). It has also been previously observed that Cu(II) 
ions are a far more efficient catalyst of intramolecular disulfide bond formation than is 
Fe(III) ions (13). As such, “free” iron in serum likely contributes negligibly to Reaction 
2. In plasma, however, Fe(III)-EDTA may play a significant role in this reaction—
potentially accounting for the higher-than-predicted initial rate of S-Cys-Alb formation 
(Fig. 2.5; Appendix A). Efforts are underway to develop a comprehensive rate model that 
takes [O2(aq)] and all relevant metals within their P/S-liganded context into account 
across the range of temperatures likely to be encountered by P/S samples. Regarding the 
different temperatures, and the effect they will have on the rate constants used in the rate 
law, a group has recently been able to determine the rate constants for the thiol disulfide 
exchange reaction of albumin at 37 °C (81). Using the rate constants determined at 37 °C 
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and the determined rate law developed here, it was possible to accurately model the S-
Cys-Alb formation at 37 °C (Fig. 3.2b). Showing that the rate model developed here is 
capable of accurately predicting the formation of S-Cys-Alb at other temperatures, once 
the rate constants have been determined.  
 It has previously been shown that the degree of air headspace above P/S samples 
stored at -20 °C does not significantly impact the overall rate of S-Cys-Alb formation 
(14). However, dissolved oxygen is involved in the oxidation of Cys to Cys-Cys 
(Reaction 2) and its potential range in an aqueous solution such as P/S is 0 - 250 µM (88, 
89), which lies in the range of the total concentration of Cys equivalents in P/S (~150 
µM). As such, the impact of nitrogen as a headspace gas (relative to air) on the formation 
profile of S-Cys-Alb in plasma was evaluated. The results (Fig. 2.7) suggest that once P/S 
samples are exposed to air, storing them under an inert atmosphere may provide a modest 
but significant ability to mitigate oxidative biomolecular damage. 
2.5 Conclusion 
The goal of this research was to determine the rate and the conditions associated 
with the occurrence of the spontaneous oxidation of albumin ex vivo. By using the 
method of initial rates and quantitatively monitoring the degree of oxidation (S-Cys-Alb 
formation) via analysis of the intact protein by electrospray ionization-mass spectrometry 
the disulfide-exchange oxidation rate constants, k1 and k2 (Reaction 1), for the reaction of 
ex vivo albumin oxidation in P/S were determined to be 0.095 ± 0.017 s-1 and 3.37 ± 0.44 
s-1, respectively.  
Using these two rate laws along with the rate law already determined for Cys 
oxidation (20), the reaction for ex vivo albumin oxidation was accurately modeled (Fig. 
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2.5), with CV values of 6.1% and 6.3% for unfortified serum and plasma samples, 
respectively. The apparent deviation in the fit of the fortified serum and plasma samples 
is possibly explained by the increased consumption of oxygen, in which, oxygen becomes 
rate limiting (Appendix B).  In validating this disulfide-exchanged based model of ex vivo 
albumin oxidation it facilitates the use of albumin oxidation as a metric of blood P/S 
integrity.  
 
 
  39 
Figures 
 
 
 
 
 
 
 
Figure 2.1: Charge deconvoluted ESI-mass spectra of the a) fully reduced and b) 
fully oxidized (S-cysteinylated) albumin employed for determination of the forward 
and reverse rate laws of the reactions shown in Reaction 1. c) To verify that no 
structural disulfide bonds were reduced in the former case, the sample was alkylated 
with maleimide. The mass shift of exactly +97 Da, with no peaks at +2*97 Da or 
higher indicate that the reduced albumin possessed only a single free Cys residue as 
expected. 
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Figure 2.2: Reaction kinetics models based on the empirically determined rate law 
(Eqns. 5-8) illustrating that by the time serum or plasma were processed from whole 
blood, the concentration of Cys drops to a near steady-state concentration of about 5 
µM—regardless of whether or not the initial concentration started at the low or high 
end of physiological Cys concentrations observed in human plasma. 
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Figure 2.3: Rates of albumin oxidation (S-cysteinylation) and reduction at 23 °C. 
a) Overall time course for albumin S-cysteinylation (oxidation) and b) initial rate 
for albumin S-cysteinylation starting with 30 µM AlbSH and 300 or 900 µM Cys-
Cys. c) Overall time course for reduction of S-Cys-Alb and d) initial rate for 
reduction of S-Cys-Alb starting with 30 µM S-Cys-Alb and 300 or 900 µM Cys. 
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Figure 2.4: Log-log plots employed to determine the reaction order for all species 
in the reversible oxidation (S-cysteinylation) of AlbSH by Cys-Cys (Reaction 1).  
The average slopes for a, b, c, and d were 1.01 ± 0.05, 0.87 ± 0.25, 1.30 ± 0.17 
and 0.96 ± 0.30, respectively. Thus, both the forward and reverse reactions were 
determined to be first order with respect to each reactant. 
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Figure 2.5: Observed and rate law model-predicted formation of S-Cys-Alb in 
matched a) serum and b) K2EDTA plasma from a healthy donor. Green (serum) and 
red (plasma) circles represent natural, unfortified serum or plasma containing initially 
measured concentrations of AlbSH = 609 µM (serum) or 605 µM (plasma); S-Cys-Alb 
= 134 µM (serum) or 138 µM (plasma); Cys-Cys = 52 µM (serum) or 58 µM (plasma);  
Cys = 5 µM (inferred, not measured, see Fig. 2.2); and Cu(II) = 12.6 µM. Blue (serum) 
and purple (plasma) cirlces represent aliquots of the same samples into which extra 
Cys-Cys and Cys were fortified, bringing the final concentration of Cys-Cys to 114 
µM (serum) or 120 µM (plasma) and Cys to 17 µM (serum & plasma). Dashed lines 
represent rate model-predicted trajectories for S-Cys-Alb formation based on 
numerical solutions to Equations 5-8 employing the rate and equilibrium constant 
parameters described in the main text. The poor model fit for samples fortified with 
extra Cys-Cys and Cys appears to be due to the concentration of dissolved oxygen, 
[O2(aq)], becoming rate limiting under these fortified conditions (Appendix B). 
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Figure 2.6: Kinetics simulations in which a) only free serum Cu(II) (0.4 µM), b) 
the ~5% of serum Cu(II) not bound to ceruloplasmin (0.63 µM), and c) all Cu(II) 
in serum (12.6 µM) is assumed to be catalytically available. Cys-Cys is 
abbreviated as CSSC in the legends. 
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Figure 2.7: Formation of S-Cys-Alb over time in aliquots of the same plasma 
incubated at 23 °C in air (green triangles) or under a nitrogen atmosphere (black 
circles). The nitrogen atmosphere modestly but significantly lowered the total 
fraction of S-Cys-Alb formed (* p < 0.01; Wilcoxon matched pairs signed-rank 
test. n = 4 per time point; error bars represent SD.) 
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Tables 
  
Table 2.1: Initial concentrations employed for determining the rate law for 
S‐cysteinylation (oxidation) of albumin (AlbSH) by cystine (Cys‐Cys). 
Values listed inside the pivot table are initial rates in units of M/s. 
Table 2.2: Initial concentrations employed for determining the rate law for 
reduction of S-cysteinylated albumin (S-Cys-Alb) by cysteine (Cys). 
Values listed inside the pivot table are initial rates in units of M/s. 
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CHAPTER 3 
DELTA S-CYSTEINYLATED ALBUMIN AS A MARKER OF BIOSPECIMEN 
INTEGRITY 
3.1 Introduction 
Collection, processing, storage and handling expose clinical biospecimens to pre-
analytical variables that, when unaccounted for, have the potential to produce misleading 
results in downstream clinical research (90-94). For blood plasma and serum (P/S) 
samples, numerous pre-analytical variables such as the type of collection tube, degree of 
tube filling, number of tube inversions, degree of hemolysis, and pre-centrifugation delay 
can quantitatively impact clinical measurements (95-98). Arguably, exposure to the 
thawed state (i.e., temperatures above -30 °C (46, 99)) is the most difficult pre-analytical 
variable to track and control over the lifetime of a P/S biospecimen—particularly at the 
individual aliquot level. 
There is widespread agreement regarding the need for robust biospecimen quality 
control (QC) / quality assurance (QA) checks in biomarker discovery and validation 
work. Yet relatively little research effort focuses on this arena. P/S specimens are among 
the most commonly employed biospecimens in biomarker-related research but, to date, 
no gold standard marker of P/S integrity has been identified and put into widespread, 
routine use. This is evidenced by the fact that despite the recent emphasis on robustness 
and reproducibility, the U.S. National Cancer Institute (NCI, part of the National 
Institutes of Health (NIH)) does not currently require any empirical evidence-based QA 
thresholds be met before pre-existing P/S specimens are employed in NCI-sponsored 
research. This QC/QA problem is widespread. For example, in 2014, 287 out of 455 NCI-
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sponsored extramural grants (63%) relied on pre-existing biospecimens; 107 of these 
sponsored projects employed pre-existing P/S (100). 
Written documentation that includes the types of specimens analyzed and the 
specimen storage conditions is now required for manuscript submissions to leading 
clinical research journals (101-103), but as experienced—and as described here—paper 
trails are insufficient to guarantee disclosure of incidents that may compromise specimen 
integrity. The possible reasons for this are rarely discussed but may range from poor note 
taking to conflicts of interest about disclosing incidents that may have resulted in 
biospecimen damage. Moreover, paper trails lack the ability to thoroughly quantify the 
molecular integrity of specimens that may have experienced minor “exposure” incidents, 
that are either not captured in the documentation or, if they were, cannot be precisely 
assigned to individual samples or aliquots. Yet if temperature-unstable or even potentially 
temperature-unstable markers are to be analyzed in a set of P/S samples, it is critically 
important to know the biomolecular integrity of every individual sample. 
This line of reasoning implies that a gold standard metric of P/S integrity should 
involve some form of empirical, quantitative biomolecular analysis that, if necessary, 
could be applied to every sample in a clinical study (whether the sample was collected for 
immediate analysis or is to be analyzed retrospectively)—even if the study employed 
thousands of P/S samples. As such, the ideal assay would focus on endogenous 
analyte(s), require a very low sample volume, require minimal sample preparation, be 
automatable from the point of fully frozen P/S to the point of generating the final report, 
and be inexpensive. Moreover, the majority, if not all, of the representative molecular 
alterations caused by the most unavoidable (bio)chemical processes that occur upon P/S 
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exposure to the thawed state should be captured by the integrity marker. Such processes 
include: 1) drifting toward an equilibrium state that is never observed in vivo, 2) ex vivo 
oxidation, due to P/S samples taking on a dissolved oxygen concentration of up to 0.25 
mM (88, 89) – a concentration that is orders of magnitude higher than that observed in 
the P/S compartment in vivo, 3) enzyme-mediated biomolecular degradation, and 4) 
macromolecular denaturation. Additionally, changes in the QA marker(s) should occur in 
the same time frame in which some of the most “fragile”, time-sensitive biomolecules 
within the P/S sample are altered beyond their original in vivo status. And finally, if 
intended as generally representative, thawed-state sensitive changes in QA marker(s) 
should neither be inhibited nor accelerated by stabilization practices that focus on a single 
mechanism of ex vivo alteration such as protease inhibitors or heat-based “inactivation”. 
 Together, these characteristics are quite stringent and are unlikely to be met by a 
single QA analyte or assay. As such, it should at least be possible to link changes in the 
QA marker to changes in specific analytes of interest by analyzing both in parallel. When 
linked empirically, this is possible for most imaginable QA markers. However, the best 
QA markers will be those for which a (bio)chemical rate law can be determined, making 
it possible for the marker(s) to serve as a molecular stopwatch for the timespan of 
thawed-state exposure—i.e., making it possible to effectively place an exposure time 
stamp on every single sample. With the rate law for the QA marker established, it would 
be possible for any investigator to link their assay(s) of interest to the QA marker by 
simply following good assay development guidelines and conducting a stability time 
course with their analyte(s) of interest. 
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In 2014 it was reported that two of the most abundant P/S proteins, albumin and 
apolipoprotein A-I, are susceptible to ex vivo oxidation events that occur over two non-
overlapping time segments in P/S specimens exposed to temperatures above -30 °C. 
These proteins were measured in a single dilute-and-shoot LC-MS assay of the intact 
proteins that required less than 1 µL of P/S (14). It was clear that albumin oxidation (S-
cysteinylation of its single free cysteine residue) would meet most of the ideal QA marker 
specifications described above, but the in vivo reference range for the fraction of albumin 
in the oxidized state and the multi-reaction rate law for the formation of S-cysteinylated 
albumin were not known. Subsequently (and as reported here), measurements were made 
that provided a conservative estimate of the population reference range for the fraction of 
albumin in its S-cysteinylated form (S-Cys-Alb), but found that it was too close to the 
maximum degree of S-cysteinylation obtained by some samples ex vivo—i.e., once 
albumin had consumed all of the free cysteine (Cys) and cystine (Cys-Cys) equivalents 
present. This limited, in theory, the useable dynamic range of S-Cys-Alb as a P/S QA 
marker. Nevertheless, the population reference range for albumin in P/S is known (104) 
and those for Cys and Cys-Cys in plasma are well estimated (79, 80). Thus assuming that 
albumin is the only significant oxidative consumer of Cys equivalents, it is possible to 
calculate that if S-Cys-Alb is measured in a fresh plasma sample and then intentionally 
driven to its maximum possible value ex vivo (14), over 99% of the human population 
under age 60 should experience a change in S-Cys-Alb between these two measurements 
(ΔS-Cys-Alb) of 11-30%. (This range increases in persons over age 60 to 16-39% 
because albumin concentrations decrease (105) and Cys-Cys concentrations increase with 
age (79)). Charge deconvoluted ESI-mass spectra of albumin that illustrate the ΔS-Cys-
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Alb phenomenon are provided in Fig. 3.1. Given that the inter-assay precision for 
measurement of S-Cys-Alb (on this scale) is 1.2% (14), ΔS-Cys-Alb as a QA marker for 
exposure of P/S samples to the thawed state was intentionally pursued. 
Reported here are the development of an assay for ΔS-Cys-Alb, estimates for the 
population reference ranges for S-Cys-Alb and ΔS-Cys-Alb, insights into the role of 
dissolved oxygen in driving S-Cys-Alb formation, the results of a blind challenge of the 
ability of ΔS-Cys-Alb to detect exposures of both group and individual P/S samples to 
the thawed state (i.e., temperatures above -30 °C), and an actual case study in which ΔS-
Cys-Alb detected and subsequently prompted disclosure of a biospecimen integrity 
discrepancy in a set of nominally pristine serum samples collected under NIH 
sponsorship. 
3.2 Materials and Methods 
3.2.1 Materials and Reagents 
Trifluoroacetic acid (TFA, 299537), HEPES (H3375) and NaCl (S7653) for 
preparation of HEPES-buffered saline solution (HBS buffer) were purchased from 
Sigma-Aldrich (St. Louis, MO). LC-MS grade Acetonitrile (TS-51101), LC-MS grade 
water (TS-51140) were purchased from ThermoFisher Scientific (Waltham, MA). All 
non-LC-MS solvents were of HPLC grade. 
3.2.2 Plasma and Serum Samples 
Fasting K2EDTA plasma and serum samples from healthy volunteers were 
collected, via forearm venipuncture, under IRB approval at Arizona State University. The 
samples were collected according to the NIH’s Early Detection Research Network blood 
collection standard operating procedures (71, 72). All tubes were filled to the proper level 
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and inverted the proper number of times (8 times for EDTA plasma and 5 times for 
serum). Within 30 minutes of collection, plasma samples were processed, aliquoted, and 
placed in a -80 °C freezer; serum samples were allowed to clot for ~ 40 minutes, then 
immediately centrifuged, aliquoted, and placed at -80 °C within 70 minutes of collection.  
Matched K2EDTA plasma and serum samples were collected under IRB approval 
from non-acute cardiac patients presenting with chest pain suggestive of coronary artery 
disease and undergoing coronary angiogram, cardiac stress test and/or coronary 
computed tomography angiography at Maricopa Integrated Health Systems. None of 
these patients had severe or end-stage renal disease (i.e., estimated glomerular filtration 
rate, eGFR < 30 mL/min*1.73 m2) and none were on hemodialysis; only 6 had eGFR 
values < 60 mL/min*1.73 m2. Patient age range was 34-83 years (mean ± SD was 59 ± 
8.5 years). Samples were collected and processed as described above for healthy 
volunteers. Times of draw, centrifugation and placement at -80 °C were recorded for 
every individual sample. Sample hemolysis was noted by visual comparison to a color 
chart, resulting in placement of samples into categories of minimal, mild, and moderate-
and-above hemolysis—corresponding to < 20 mg hemoglobin/dL, 20-50 mg/dL and > 50 
mg/dL, respectively. 
Serum specimens for the case study of pre‐existing samples were collected under 
IRB approval from stage I lung cancer patients and corresponding age, gender and 
smoking‐status matched controls. These samples were collected under NIH‐sponsorship 
by seasoned investigators with well‐defined, matched standard operating procedures. 
Briefly, serum samples were collected into red top tubes (BD Vacutainer catalog no. 
366430). These were allowed to sit upright at room temperature for 30‐60 minutes after 
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blood was drawn to allow the clot to form. If the blood was not centrifuged immediately 
after the clotting time, the tubes were refrigerated at 4 °C for no longer than 24 hours. 
After clotting, samples were centrifuged at 1,200 RCF for 20 minutes at room 
temperature. Aliquots were then placed into 2‐mL cryovials and stored at ‐80 °C. Most 
case and control samples were processed and placed at ‐80 °C within 2‐3 hours of 
collection. Cancer patients were 69% female / 31% male and controls were 71% female / 
29% male. The average age (mean ± SD) of the cancer patients and controls was 71.9 ± 
9.2 yrs and 68.4 ± 8.1 yrs, respectively. Cancer patients had a slightly lower average 
number of smoking pack years (33.9 pack yrs) compared to the controls (37.3 pack yrs). 
All P/S samples were coded and de‐identified prior to transfer to the analytical 
laboratory. All human subject experiments were conducted according to the principles 
expressed in the Declaration of Helsinki. 
3.2.3 S-Cys-Alb and ΔS-Cys-Alb Assay Sample Preparation 
P/S samples were prepared for injection onto the LC-MS by 1000x dilution in 
0.1% (v/v) TFA. Typically, 0.5 or 1µL was mixed with 500 or 1000 µL of 0.1% TFA. 
Once diluted, S-Cys-Alb measurements are stable for over 16 hrs at 10 °C (14). For 
measurement of ΔS-Cys-Alb, 9 µL of residual P/S sample was then placed into a 0.6-mL 
Eppendorf snap-cap polypropylene test tube and incubated in an oven set at 37 °C for 18 
hrs. Following this period, the sample was diluted 1000x in 0.1% TFA then injected onto 
the LC-MS. The difference in S-Cys-Alb before and after this 18-hr incubation at 37 °C 
constitutes ΔS-Cys-Alb. 
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3.2.4 Blind Challenge 
P/S samples were acquired from a single healthy donor on three different draw 
dates. These samples were divided into 120 aliquots of 50 µL each and were evenly 
distributed to the grouped and individual treatment sets. Each sample was marked with an 
identifier code to enable clear distinction between samples by the mediator, but the key to 
the identifier codes was not disclosed to the analyst until completion of the experiments 
and data interpretation had occurred. The sixty samples in each set were divided into ten 
groups consisting of three serum and plasma samples (one serum and plasma sample 
from each blood draw), and each group was assigned a treatment condition (Table 3.1). 
The samples present in the grouped set were given distinct labels consisting of a number 
(1-10) and a letter (A-F), with the number denoting samples in each grouped treatment 
condition. The role of the number on each of these samples was disclosed to the analyst, 
giving knowledge on the samples present in each group, but the treatment condition for 
each group and the letter distinction were not revealed. The labels used to distinguish 
samples in the individual set were created using a 4-digit random number generator to 
inhibit the analyst from identifying samples present in the same treatment condition. 
After completion of the assigned treatment condition, all samples were stored at - 80 °C 
until further analysis was completed. 
The analyst then used the ΔS-Cys-Alb assay by using 10 µL of the P/S sample, of 
which 1 µL was used to measure the initial oxidation of albumin, the remaining 9 µL was 
incubated overnight at 37 °C to intentionally drive it to maximum oxidation. Oxidation 
was again measured, the difference in these measurements, called ΔS-Cys-Alb was 
calculated. 
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3.2.5 Case Vs. Control Real Life Samples 
The samples were collected under NIH-sponsorship by seasoned investigators 
with well-defined standard operating procedures. Samples were analyzed using the ΔS-
Cys-Alb assay by using 10 µL of the P/S sample, of which 1 µL was used to measure the 
initial oxidation of albumin, the remaining 9 µL was incubated overnight at 37 °C to 
intentionally drive it to maximum oxidation. Oxidation was again measured, the 
difference in these measurements, ΔS-Cys-Alb was calculated. 
3.2.6 Data Analysis 
3.2.6.1 LC-ESI-MS Analysis 
Relative quantification of intact albumin proteoforms was done by liquid 
chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) on a Dionex 
Ultimate 3000 HPLC equipped with a 1:100 flow splitter connected to a Bruker maXis 
4G quadrupole-time-of-flight (Q-TOF) mass spectrometer. A trap-and-elute form of LC-
MS was carried out in which 5 µL of sample was loaded via a loading pump at 10 μl/min 
in 80% water containing 0.1% formic acid (Solvent A) / 20% acetonitrile (Solvent B) 
onto an Optimize Technologies protein captrap configured for uni-directional flow on a 
10-port diverter valve. The trap was then rinsed at this solvent composition with the 
HPLC loading pump at 10 µl/min for 3 minutes. The flow over the captrap was then 
switched to the micro pump, which was set at a flow rate of 3 µL/min and composition of 
65/35 A/B. This composition was held until 4.5 min. From 4.5-4.6 min. the composition 
was ramped to 55/45 A/B then held.  From 7.5-7.6 min. the composition was ramped to 
20/80 A/B then held. Then from 9.4-9.5 min. the composition was ramped back to 65/35 
A/B in preparation for the next injection.  Following the valve switch at 3 minutes, the 
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captrap eluate was directed to the mass spectrometer operating in positive ion, TOF-only 
mode, acquiring spectra in the m/z range of 300 to 3000. ESI settings for the Agilent 
G1385A capillary microflow nebulizer ion source were as follows: End Plate Offset -500 
V, Capillary -4500 V, Nebulizer nitrogen 3 Bar, Dry Gas nitrogen 3.0 L/min at 225°C. 
Data were acquired in profile mode at a digitizer sampling rate of 4 GHz. Spectra rate 
control was by summation at 1 Hz. 
3.2.6.2 Data Analysis 
As previously described (14), approximately 1 minute of recorded spectra were 
averaged across the chromatographic peak apex of albumin. The electrospray ionization 
charge-state envelope was deconvoluted with Bruker DataAnalysis v3.4 software to a 
mass range of 1000 Da on either side of any identified peak. Deconvoluted spectra were 
baseline subtracted, and all peak heights were calculated, tabulated and exported to a 
spreadsheet for further analysis. Peak heights were used for quantification as opposed to 
peak areas, because of the lack of baseline resolution for some of the peaks. 
3.3 Results 
3.3.1 Development of the ΔS-Cys-Alb Assay 
The highest temperature to which human P/S is exposed in its normal in vivo 
environment is 37 °C; as such, this temperature was chosen as the incubation temperature 
for the ΔS-Cys-Alb assay. To determine the time required to maximize S-Cys-Alb, as 
well as the impact of blood collection type and the effect of varying Cys and Cys-Cys 
concentrations on the time required to reach a maximum value of S-Cys-Alb, a matched 
collection of K2EDTA plasma, sodium heparin plasma, and serum from a healthy donor 
was obtained and S-Cys-Alb was measured in the freshly processed samples. Portions of 
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each specimen were then fortified with an additional 1 µM Cys and 10 µM Cys-Cys or 2 
µM Cys and 20 µM Cys-Cys. These added concentrations represent approximately 1-2 
standard deviations (SDs) of the mean values of ~ 10 µM Cys and ~ 62 µM Cys-Cys seen 
in the plasma of typical donors (79, 80). Nine-microliter aliquots of each unique P/S 
sample were then incubated in sealed 0.6-mL tubes at 37 °C and S-Cys-Alb was 
measured at 4, 18, 24 and 30-hr time points (three separate 9-µL aliquots were made for 
each time point).  Differences between matched serum and plasma were negligible, with 
all specimens reaching their maximum value of S-Cys-Alb by 18 hrs. Addition of Cys 
and Cys-Cys to the samples resulted in a higher maximum value of S-Cys-Alb but did not 
alter the time required to reach it (Fig. 3.2).    
3.3.2 ΔS-Cys-Alb in Fresh Samples from Cardiac Patients 
Non-acute cardiac patients presenting with chest pain, suggestive of coronary 
artery disease, undergoing coronary angiogram cardiac stress test and/or coronary 
computed tomography angiography at the recommendation of a cardiologist are likely to 
be individuals under continual low to moderate levels of systemic oxidative stress—a 
situation that could potentially raise their endogenous levels of S-Cys-Alb above that of 
nominally healthy individuals. As such, these cardiac patients represented a clinical 
population that could potentially pose a challenge to the theoretically usable dynamic 
range of the ΔS-Cys-Alb assay. To estimate the typical values of S-Cys-Alb and ΔS-Cys-
Alb observed in fresh samples from these patients, matched K2EDTA plasma and serum 
samples were collected from 30 of them. P/S specimens were collected under rigorous 
guidelines to ensure the highest possible sample quality. Fresh K2EDTA plasma and 
serum were found to have similar but significantly different values of S-Cys-Alb (paired 
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t-test, p < 0.001; Fig. 3.3). Following incubation of 9-µL aliquots at 37 °C for 18 hrs, S-
Cys-Alb was measured again and the difference between the two measurements was 
recorded as ΔS-Cys-Alb. Both the maximum value of S-Cys-Alb and ΔS-Cys-Alb were 
found to be significantly higher in plasma than serum (paired t-test, p < 0.001; Fig. 3.3). 
All distributions were Gaussian (D’Agostino & Pearson normality test; p > 0.05). The 
mean value of ΔS-Cys-Alb in cardiac patient plasma (± SD) was 0.22 ± 0.039 and in 
serum was 0.17 ± 0.030 (when plasma and serum data are combined, the mean ± SD is 
0.20 ± 0.041). Empirically, these values suggest that ΔS-Cys-Alb values in 95% of fresh 
cardiac patient plasma and serum samples will fall in the ranges of 14% - 30% and 11% - 
23%, respectively. 
3.3.3 Blind Challenges of ΔS-Cys-Alb 
Two separate challenges were conducted for ΔS-Cys-Alb as a marker of P/S 
exposure to thawed conditions in which the analyst was blinded to sample identities. The 
first study was a group-wise challenge wherein discrete groups of samples were either 
exposed to thawed conditions or properly stored at -80 °C as groups. The second blind 
challenge involved proper storage or mistreatment of discrete, individual samples. Prior 
to unblinding, the analyst was only aware that there would be a group-wise challenge and 
an individual sample challenge; the analyst was unaware of any other aspect of the 
experimental design described below. 
3.3.3.1 Group-wise Blind Challenge  
Matched plasma and serum were collected from the same individual on three 
separate days, all spaced at least six days apart. This produced six unique but not highly 
different samples. Ten 50-µL aliquots were created from each sample, creating ten 
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groups, each of which contained one aliquot each of the original six specimens. These 
groups were then randomly assigned: two groups were kept continually at -80 °C, and 
one group was subjected to each of the following eight conditions: 23 °C for 2 hrs, 23 °C 
for 4 hrs, 23 °C for 6 hrs, 23 °C for 8 hrs, 4 °C for 8 hrs, 4 °C for 16 hrs, -20 °C for 24 
hrs, and -20 °C for 48 hrs (Table 3.1). The samples were then given to the analyst with 
only a coded identifier on each sample that corresponded to its unique group. ΔS-Cys-
Alb was then measured in each sample (Fig. 3.4a). The distributions of all data sets 
overlapped to some degree, indicating that it would likely be difficult to distinguish 
control group(s) from mistreated group(s). As such, data were analyzed using a statistical 
approach designed to limit type II errors (i.e., one-way ANOVA followed by uncorrected 
Fisher’s LSD with p < 0.1 serving as the cutoff for statistical significance). Based on this 
analysis, it was clear that Groups 1 and 3 had higher mean values of ΔS-Cys-Alb than all 
other groups, except for Group 7, whose status was unclear. Moreover, the ΔS-Cys-Alb 
values in Groups 1 and 3 were consistent with fresh samples or those kept at -80 °C (cf. 
Fig. 3.3). Thus Groups 1 and 3 were named by the analyst as control groups. Group 7 
could not be definitively categorized but was guessed/presumed to also be a properly 
handled control group. All other groups were assigned as having been exposed to thawed 
conditions of some sort. Upon unblinding it was revealed that all assignments except for 
Group 7 had been made correctly (Fig. 3.4a). 
3.3.3.2 Individual Blind Challenge 
Ten additional 50-µL aliquots were made from the six samples described in the 
preceding paragraph, producing a total of 60 specimens. These aliquots were made at the 
same time as the others to avoid an additional freeze-thaw cycle. Twelve of these 
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specimens (n = 2 aliquots of each of the original six P/S samples) were kept at -80 °C. 
One aliquot each of the original six P/S samples was then subjected to each of the 
following eight conditions: 23 °C for 24 hrs, 23 °C for 48 hrs, 23 °C for 72 hrs, 23 °C for 
7 days, 4 °C for 7 days, 4 °C for 14 days, -20 °C for 60 days, -20 °C for 90 days (Table 
3.1). Each individual test tube had only a single, completely unique coded identifier on it. 
The analyst was then given the samples and ΔS-Cys-Alb was measured in each sample. 
Since statistical analysis cannot be conducted on single samples, a ΔS-Cys-Alb integrity 
cutoff had to be assigned. Based on the Gaussian distribution of ΔS-Cys-Alb in P/S from 
nominally unhealthy patients that have been collected to date (Fig. 3.3), it can be 
predicted that 99% of fresh P/S samples have ΔS-Cys-Alb values in the range of 9% to 
30%. This range was determined based on the mean ± 2.58 SDs of the combined plasma 
and serum samples represented in Fig. 3.3b.  Thus, a ΔS-Cys-Alb value of 0.090 (or 
9.0%) was set as the cutoff for this individual sample-level blind challenge. Using this 
cutoff, all 60 individual specimens were categorized correctly (Fig. 3.4b).  
3.3.4 Case Study: Application of ΔS-Cys-Alb 
Following development of the ΔS-Cys-Alb assay, an occasion arose in the 
laboratory in which it was needed. In short, a set of serum samples from stage I lung 
cancer patients and corresponding age, gender and smoking-status matched controls were 
undergoing glycan “node” analysis (106-110) as part of an unrelated project. The samples 
were collected under NIH-sponsorship by seasoned investigators with well-defined SOPs 
and, on paper, there should not have been any specimen integrity problems. As part of the 
glycan “node” assay, relative blood glucose concentrations were (unintentionally) 
determined. The relative blood glucose concentrations in these samples indicated 
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unexpectedly elevated levels of blood glucose in the cases. It has been previously 
observed that albumin glycation increases significantly over time in P/S samples exposed 
to thawed conditions (Chapter 4); as such, even though there was a pristine paper trail 
associated with these samples, it was decided to measure ΔS-Cys-Alb in them. The mean 
values of ΔS-Cys-Alb were significantly different between the cases and controls (p < 1 x 
10-20; student’s t-test) and there was nearly no overlap in their ΔS-Cys-Alb distributions 
(Fig. 3.5). Since ΔS-Cys-Alb is not a marker of stage I lung cancer, these data indicated 
an integrity discrepancy between the two sets of serum samples. Upon showing these data 
to the clinical investigators who had provided the samples, it was ultimately disclosed 
that the -80 °C freezers in which the control samples had been stored had experienced a 
power outage for about 3-4 days during a natural disaster. Using the combined rate law 
model described in (Chapter 2 Equations 5-8) in combination with average population 
values for total albumin, AlbSH, S-Cys-Alb, Cys, Cys-Cys and total copper in fresh 
serum, it was estimated that the control serum samples had been exposed to the 
equivalent of room temperature (~ 23 °C) for an average of ~ 1.2 days—an estimate that 
aligns with the fact that despite losing power for 3-4 days, the freezers had not been 
opened. 
3.4 Discussion 
The fraction of albumin in the S-cysteinylated form, S-Cys-Alb, increases to a 
maximum value over time when P/S samples are exposed to temperatures above -30 °C 
(14). As shown here, S-Cys-Alb, rarely exceeds 40% in fresh P/S samples from cardiac 
patients (Fig. 3.3a). The range of S-Cys-Alb observed in fresh samples, however, 
overlaps with the range of maximum values of S-Cys-Alb observed after samples have 
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been intentionally incubated in the thawed state (Fig. 3.3a). These facts undermine the 
utilization of S-Cys-Alb as a biomarker of oxidative stress unless extreme care is taken to 
rigorously document specimen exposure to thawed conditions prior to measurement; they 
also preclude the use of S-Cys-Alb as a self-contained marker of P/S integrity. 
Nevertheless, as also illustrated here, ΔS-Cys-Alb values are above 11% in most 
fresh plasma and serum samples (Fig. 3.3b; range: 12.1% - 29.2%; mean ± SD: 0.20 ± 
0.04). This observed range of ΔS-Cys-Alb in P/S lies in-line with the theoretical range 
(11 – 39%) of ΔS-Cys-Alb that can be predicted based on the average plasma 
concentrations of albumin, Cys-Cys and Cys observed in the human population (79, 80, 
104). This predicted range of ΔS-Cys-Alb does not consider the possibility that other P/S 
proteins, such as alpha-1-antitrypsin (111) may consume Cys-Cys/Cys equivalents in 
thawed P/S—potentially accounting for slightly lower mean values of ΔS-Cys-Alb than 
predicted in both plasma and serum. 
The major source of the discrepancy in ΔS-Cys-Alb between matched plasma and 
serum samples was not the initial value of S-Cys-Alb but was rather the maximum value 
reached following incubation for 18 hrs at 37 °C (Fig. 3.3). This discrepancy is not 
observed in all samples; yet the source of the discrepancy is unclear as it is not related to 
the difference in pre-centrifugation delay between the matched serum and plasma 
samples, nor is it related to serum clotting time (Fig. 3.6).  Neither is it related to the 
visually documented degree of hemolysis or the difference in degree of hemolysis 
between plasma and serum. Clotting factors such as Factor XIII contain free Cys residues 
and may consume some free Cys and/or Cys-Cys equivalents during the clotting 
process—which in some, but not necessarily all cases (Fig. 3.6) may consume a 
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significant portion of available free Cys and/or Cys-Cys equivalents, making these 
equivalents unavailable for reaction with albumin during serum storage. Regardless of the 
source of the modest difference between plasma and serum, the facts that 1) ΔS-Cys-Alb 
inevitably falls from the ranges in the preceding paragraph to zero once the relevant 
reactions (Section 2.3.1.1 Reactions 1 and 2) in ex vivo P/S samples have reached 
equilibrium (i.e., 18 hrs at 37 °C (Fig. 3.2), ~4 days at 23 °C (14) (Figs. 2.5 and 2.7), and 
~ 60 days at -20 °C (14) (Fig. 3.7)), and 2) the S-Cys-Alb assay is highly precise (1.2% 
inter-assay precision on this scale) (14), support the utilization of ΔS-Cys-Alb as a 
marker of P/S exposure to thawed conditions. 
Two other known potential assay confounders place only minor limits on such use 
of ΔS-Cys-Alb. First, patients with poor kidney function who require hemodialysis are 
susceptible to abnormally elevated levels of circulating Cys and Cys-Cys (112); they may 
also have elevated levels of S-Cys-Alb (113-116)—though these studies did not explicitly 
consider the possible ex vivo formation of S-Cys-Alb. Elevated S-Cys-Alb in vivo does 
not impact ΔS-Cys-Alb, but elevated circulating Cys and Cys-Cys may account for ΔS-
Cys-Alb levels above 40%. Such samples would take slightly longer periods of time to 
reach the lower values of ΔS-Cys-Alb considered to represent samples exposed to thawed 
conditions. However, if the samples are known to come from kidney failure patients, this 
fact can be considered vis-à-vis the rate law established in Chapter 2. Second, human 
albumin mutations represent the only qualitative ΔS-Cys-Alb assay confounder. These 
are rare in most populations (with average rates of 0.001 – 0.03% (117))—but even if 
such samples were measured, the highly accurate mass spectrometry measurements of the 
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intact protein on which the ΔS-Cys-Alb assay is based would detect all but the 
inconsequential isobaric protein variants. 
Conceptually, the development of a low-volume, inexpensive P/S integrity marker 
that is based on known chemical reactions and their established rate laws (i.e., 
mathematical model—Chapter 2) and can be used to forensically approximate the 
amount of time a specimen has spent at the equivalent of room temperature, represents a 
critical waypoint in biobanking QA. Yet its development does not represent a fix-all QA 
remedy: Ultimately, setting a ΔS-Cys-Alb cutoff that defines samples as “bad” depends 
on the intended use(s) of the samples. Moreover, prioritizing the tradeoff between 
keeping/using “bad” samples and throwing away “good” samples will always involve 
economic as well as scientific considerations. This means that functionally clarifying the 
meaning of QA marker measurements will always be context-dependent. However, 
because the kinetic behavior of ΔS-Cys-Alb has been well defined (at least at 23 °C), the 
only “added ingredient” necessary to link clinically important biomarkers of interest to 
ΔS-Cys-Alb is to independently characterize their empirical stability in P/S at room 
temperature—which is often done as part of careful analytical method development. 
Once this has been done, the time point at which initial instability occurred can be 
mapped to a clinical marker-specific ΔS-Cys-Alb cutoff vis-à-vis the kinetics model 
established in Chapter 2. This will allow the rapid, inexpensive, low-volume 
measurement of ΔS-Cys-Alb in unknown samples to provide direct insights into the 
validity of clinical biomarker measurements in any archived P/S specimen—regardless of 
their presumed storage and handling history.    
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Rate laws and mathematical modeling aside, the blind challenges conducted 
provide an empirical sense of the ability of ΔS-Cys-Alb to detect P/S exposures to 
thawed conditions. They also underscore the fact that very minor exposures to thawed 
conditions (e.g., 2 hrs at 23 °C; Fig. 3.4) can be detected. However, as would be the case 
with any QA marker, only in the context of distinct groups of samples that have been 
stored or handled separately—a scenario which is actually quite common amongst 
archived specimens that are brought together for a discovery or validation study. 
Assuming the averages and SDs observed here (Fig. 3.3) are representative of clinical 
biospecimens in general, measurement of ΔS-Cys-Alb in three P/S specimens from a 
questionable group will provide greater than 90% power to detect a value of ΔS-Cys-Alb 
that is significantly lower than 2 SDs below the mean values of ΔS-Cys-Alb found in the 
fresh P/S of cardiac patients here (α = 0.05). That stated, testing all samples within a 
questionable group is the only way to ensure that only pristine samples that have 
experienced minimal exposure to temperatures above -30 °C are employed in clinical 
studies.  Mistreatment of one-off, individual P/S specimens can also be detected—but this 
must be done based on absolute terms—i.e., detection of a ΔS-Cys-Alb value below a 
pre-established absolute threshold. 
To set an optimal balance between type I and type II errors, the integrity threshold 
for ΔS-Cys-Alb in individual samples was established at 9.0%, which is 2.58 standard 
deviations below the mean value observed in combined fresh plasma and serum samples 
from nominally unhealthy patients (Fig. 3.3). The distribution of these values was 
Gaussian; thus, in theory, 99% of pristine samples would fall above this cutoff, while 
most samples that were moderately mistreated (e.g., 24 hrs at 23 °C or 7 days at 4 °C) 
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would fall below the cutoff. This proved to be true in practice (Fig. 3.4b), resulting in 
zero sample mischaracterizations in the individual-sample blind challenge. Clearly the 
chosen mistreatment conditions played a role in defining the success or failure of the 
blind challenge studies. The specific mistreatment conditions were chosen, however, 
because they represented realistic mild-to-moderate thawed-state conditions to which 
“real life” P/S samples may be exposed to during their lifetimes. 
The realistic nature of thawed-state exposure conditions that result in ΔS-Cys-Alb 
values above zero but below the 9.0% threshold was proven in the case study of serum 
samples presented (Fig. 3.5). This case not only demonstrated the ability of ΔS-Cys-Alb 
to detect integrity problems in clinical samples that were considered on paper to be 
pristine, but also illustrated the ability of the associated rate law model to back-calculate 
the approximate time frame over which the samples were exposed to the equivalent of 
room temperature conditions. Age-weighted population averages of initial reactant and 
product concentrations were employed in this estimate. If ever deemed necessary 
however, age range-specific in vivo concentrations of albumin (105), Cys and Cys-Cys 
(79, 80) are available and can be employed in conjunction with the rate law. Rate law-
based calculations of ΔS-Cys-Alb values vs. ex vivo time at 23 °C in persons under 60 
(Table 3.2), over 60 (Table 3.3) and in U.S. population age-weighted group (Table 3.4) 
are provided for reference.   
3.5 Conclusions 
ΔS-Cys-Albumin, measured via a low-volume (≤ 10 µL), dilute-and-shoot, 
LC/MS assay, is an effective biomolecular oxidation-based QC/QA marker for P/S 
exposure to thawed conditions (i.e., > -30 °C). Though in need of fine tuning vis-à-vis 
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determination of the rate law for oxidation of Cys to Cys-Cys under conditions highly 
specific to ex vivo plasma and serum, the multi-reaction rate law governing the formation 
of S-Cys-Alb has been determined and empirically shown to be capable of accurately 
predicting S-Cys-Alb formation in P/S (Chapter 2); thus when population averages of the 
relevant reactants are assumed, the combined rate law facilitates estimation of the time 
frame over which P/S samples with unknown storage & handling histories have been 
exposed to the equivalent of room temperature conditions. As such, the stability of any 
clinical biomarker of interest can readily be linked to ΔS-Cys-Alb by conducting a room 
temperature stability study of the marker—regardless of the mechanism by which it 
exhibits its own instability. When P/S samples are grouped, ΔS-Cys-Alb can detect room 
temperature exposures as little as 2 hrs—yet ~3-4 days at room temperature are required 
for P/S samples to reach the ΔS-Cys-Alb minimum value of zero. Based on the survey of 
fresh, matched plasma and serum from cardiac patients reported here, as little as 3 
representative samples from an unknown group are required to provide greater than 90% 
power to detect a ΔS-Cys-Alb value that is significantly lower than 2 SDs below the 
mean values of ΔS-Cys-Alb observed in fresh samples from cardiac patients (α = 0.05). 
Mistreatment of individual samples can also be detected when their ΔS-Cys-Alb values 
are 2.5 SDs below these means (i.e., < 9%). ΔS-Cys-Alb identifies poor-quality P/S 
specimens and will, when properly deployed, prevent their inclusion in clinical research 
studies. 
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Figures 
 
 
 
 
 
 
 
 
 
Figure 3.1: Charge deconvoluted ESI-mass spectra of albumin that illustrate ΔS-
Cys-Alb. The black spectrum is from a fresh sample obtained immediately after 
centrifugation. The red spectrum is from the same sample stored for 60 days at -
20 °C. As indicated, small fractions of albumin are N-terminally truncated, and 
both the native and S-cysteinylated forms may be glycated. 
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Figure 3.2: Determination of the time required at 37 °C to maximize S-Cys-Alb in 
P/S samples. a) Nine-microliter aliquots of matched K2EDTA plasma, sodium heparin 
plasma, and serum from a healthy donor were incubated in closed vials at 37 °C for up 
to 30 hrs. No significant differences were found between plasma and serum or 
between the two types of plasma. No changes were observed after 18 hrs at 37 °C.      
n = 3 per data point; error bars represent SD. b) Each P/S sample was divided into 3 
portions; one was left unmodified, to the second was added 1 µM Cys and 10 µM 
Cys-Cys, and to the third was added 2 µM Cys and 20 µM Cys-Cys. The addition of 
Cys and Cys-Cys results in an increase in the maximum value of S-Cys-Alb observed, 
but does not increase the time frame required to reach the maximum obtainable value 
of S-Cys-Alb at 37 °C. Obtained data agrees with the predicted data obtain using the 
determined rate law and the rate constants at 37 °C previously determined (81). Data 
from both types of plasma and serum were pooled and are displayed together as mean 
± SD (n = 9 per data point).  
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Figure 3.3: S-Cys-Alb and ΔS-Cys-Alb in fresh, rapidly processed samples from 
cardiac patients. a) S-Cys-Alb and maxed-out S-Cys-Alb observed in fresh samples 
from matched K2EDTA plasma and serum samples from cardiac patients undergoing 
coronary angiogram, cardiac stress test and/or coronary computed tomography 
angiography. b) ΔS-Cys-Alb, calculated from panel a) by taking individual sample 
differences between maxed-out S-Cys-Alb and S-Cys-Alb. Error bars represent mean 
± SD; n = 30 per group; * indicates a significant difference between means of 
indicated groups with p < 0.0001, paired t-tests. 
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Figure 3.4: Results from blinded challenges of the ability of ΔS-Cys-Alb to 
distinguish a) groups of samples exposed to various thawed conditions (listed below 
each group), and b) individual samples exposed to various thawed conditions 
including 23 °C for 24 hrs, 23 °C for 48 hrs, 23 °C for 72 hrs, 23 °C for 7 days, 4 °C 
for 7 days, 4 °C for 14 days, -20 °C for 60 days, -20 °C for 90 days; controls kept at    
-80 °C. 
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Figure 3.5: ΔS-Cys-Alb results from a case study of serum samples with an excellent 
pedigree but in which an integrity discrepancy was suspected (see main text for 
details). The values of ΔS-Cys-Alb in the controls barely overlapped with those of the 
cases (receiver operating characterisitic curve c-statistic = 0.96) and the mean value of 
ΔS-Cys-Alb was strongly significantly lower in the controls than it was in the cases  
(p < 1 x 10-20; two-tailed student’s t-test). ΔS-Cys-Alb in the stage I lung cancer 
cases was essentially the same as it was in fresh samples from cancer free patients (cf. 
Figs. 3.3 and 3.4), meaning that the difference in ΔS-Cys-Alb between the cases and 
controls in this set cannot be due to the presence of cancer—leaving variable exposure 
to the thawed state as the only reasonable explanation for the difference observed. 
This was subsequently confirmed by the sample providers. Notably, the initial 
measurement of S-Cys-Alb revealed a clear (albeit less robust) separation between the 
controls and cases, but the maximum degree of S-Cys-Alb observed following the 
intentional incubation at 37 °C for 18 hrs did not vary between the controls and cases. 
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Figure 3.6: The difference between matched plasma and serum sample ΔS-Cys-Alb 
values was not correlated to a) the pre-centrifugation time difference between plasma 
and serum or b) serum pre-centrifugation (clotting) time. (p > 0.5 in both cases; 
Pearson correlation). 
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Figure 3.7: Time courses of S-Cys-Alb formation at -20 °C in matched a) plasma and 
b) serum with and without fortification with an extra 62 µM Cys-Cys and 12 µM Cys. 
Time points from unfortified control aliquots stored at -80 °C are shown for 
comparison. 
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Tables 
 
 
  Group Treatment Group Treatment
1 -80°C 1 -80°C
2 4° C for 7 days 2 4°C for 16 hours
3 -80°C 3 -80°C
4 25°C for 24 hours 4 25°C for 2 hours
5 -20°C for 60 days 5 -20°C for 24 hours
6 -20°C for 90 days 6 -20°C for 48 hours
7 4°C for 14 days 7 4°C for 8 hours
8 25°C for 48 hours 8 25°C for 4 hours
9 25°C for 72 hours 9 25°C for 6 hours
10 25°C for 7 days 10 25°C for 8 hours
Group ChallengeIndividual Challenge
Table 3.1: Assigned treatment conditions for the Individual and Group 
Blind challenge. 
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a All initial concentrations are based on population averages, the sources of which 
are provided in the main text. Parameters common to all models: k3 = 0.13 M
-1 s-1, 
Ky = 2.0 x 10
-6 M, Kz = 3.5 x 10
-4 M, Cu(II) in plasma = 18.7 x 10-6 M (104), Cu(II) 
in serum = 9.35 x 10-6 M (half of plasma as per main text) 
 
b [Cys-Cys]0 = 62 x 10
-6 M, [Cys]0 = 5 x 10
-6 M, Serum:[AlbSH]0 = 487 x 10
-6 M, 
[SCysAlb]0 = 166 x 10
-6 M, Plasma:[AlbSH]0 = 478 x 10
-6 M, [SCysAlb]0 = 175 x 
10-6 M. [AlbSH]0 and [SCysAlb]0 differ slightly in serum and plasma based on 
results shown in Fig. 3.3. 
Table 3.2: Oxygen-independent rate law-based calculations of ΔS-Cys-
Alb over time at 23 °C for people under 60 years. a 
Serum Plasma Serum Plasma
Time at Room 
Temperature 
(Hrs)
ΔS-Cys-Alb ΔS-Cys-Alb
Time at Room 
Temperature 
(Hrs)
ΔS-Cys-Alb ΔS-Cys-Alb
0 19.3 19.5 49 2.5 2.1
1 18.2 18.2 50 2.4 2.0
2 17.0 17.0 51 2.3 1.9
3 16.0 15.9 52 2.3 1.9
4 15.1 15.0 53 2.2 1.8
5 14.2 14.1 54 2.1 1.8
6 13.4 13.2 55 2.1 1.7
7 12.7 12.5 56 2.0 1.7
8 12.0 11.8 57 2.0 1.6
9 11.4 11.1 58 1.9 1.6
10 10.9 10.5 59 1.9 1.5
11 10.3 10.0 60 1.8 1.5
12 9.8 9.4 61 1.8 1.4
13 9.4 9.0 62 1.7 1.4
14 8.9 8.5 63 1.7 1.3
15 8.5 8.1 64 1.6 1.3
16 8.1 7.7 65 1.6 1.3
17 7.8 7.3 66 1.5 1.2
18 7.4 7.0 67 1.5 1.2
19 7.1 6.7 68 1.5 1.2
20 6.8 6.4 69 1.4 1.1
21 6.6 6.1 70 1.4 1.1
22 6.3 5.8 71 1.4 1.1
23 6.0 5.6 72 1.3 1.0
24 5.8 5.3 73 1.3 1.0
25 5.6 5.1 74 1.3 1.0
26 5.4 4.9 75 1.2 1.0
27 5.2 4.7 76 1.2 0.9
28 5.0 4.5 77 1.2 0.9
29 4.8 4.3 78 1.1 0.9
30 4.6 4.1 79 1.1 0.9
31 4.4 4.0 80 1.1 0.8
32 4.3 3.8 81 1.1 0.8
33 4.1 3.7 82 1.0 0.8
34 4.0 3.5 83 1.0 0.8
35 3.9 3.4 84 1.0 0.7
36 3.7 3.3 85 1.0 0.7
37 3.6 3.1 86 0.9 0.7
38 3.5 3.0 87 0.9 0.7
39 3.4 2.9 88 0.9 0.7
40 3.3 2.8 89 0.9 0.7
41 3.2 2.7 90 0.8 0.6
42 3.1 2.6 91 0.8 0.6
43 3.0 2.5 92 0.8 0.6
44 2.9 2.4 93 0.8 0.6
45 2.8 2.4 94 0.8 0.6
46 2.7 2.3 95 0.8 0.6
47 2.6 2.2 96 0.7 0.5
48 2.5 2.1
Under 60 Years Old 
b
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Table 3.3: Oxygen-independent rate law-based calculations of ΔS-Cys-
Alb over time at 23 °C for people over 60 years. a 
a All initial concentrations are based on population averages, the sources of which are 
provided in the main text. Parameters common to all models: k3 = 0.13 M
-1 s-1, Ky = 
2.0 x 10-6 M, Kz = 3.5 x 10
-4 M, Cu(II) in plasma = 18.7 x 10-6 M (104), Cu(II) in 
serum = 9.35 x 10-6 M (half of plasma as per main text) 
 
c [Cys-Cys]0 = 79 x 10
-6 M, [Cys]0 = 5 x 10
-6 M, Serum: [AlbSH]0 = 460 x 10
-6 M, 
[SCysAlb]0 = 157 x 10
-6 M, Plasma: [AlbSH]0 = 452 x 10
-6 M, [SCysAlb]0 = 165 x 
10-6 M. [AlbSH]0 and [SCysAlb]0 differ slightly in serum and plasma based on 
results shown in Fig. 3.3. 
Serum Plasma Serum Plasma
Time at Room 
Temperature 
(Hrs)
ΔS-Cys-Alb ΔS-Cys-Alb
Time at Room 
Temperature 
(Hrs)
ΔS-Cys-Alb ΔS-Cys-Alb
0 25.7 25.9 49 3.7 3.2
1 24.1 24.3 50 3.6 3.1
2 22.7 22.8 51 3.5 3.1
3 21.3 21.4 52 3.4 3.0
4 20.1 20.1 53 3.3 2.9
5 19.0 19.0 54 3.2 2.8
6 18.0 17.9 55 3.1 2.7
7 17.1 16.9 56 3.0 2.6
8 16.2 16.0 57 3.0 2.6
9 15.4 15.2 58 2.9 2.5
10 14.7 14.4 59 2.8 2.4
11 14.0 13.7 60 2.7 2.4
12 13.3 13.0 61 2.7 2.3
13 12.7 12.4 62 2.6 2.2
14 12.2 11.9 63 2.5 2.2
15 11.7 11.3 64 2.5 2.1
16 11.2 10.8 65 2.4 2.1
17 10.7 10.3 66 2.3 2.0
18 10.3 9.9 67 2.3 1.9
19 9.9 9.5 68 2.2 1.9
20 9.5 9.1 69 2.2 1.8
21 9.1 8.7 70 2.1 1.8
22 8.8 8.3 71 2.1 1.8
23 8.4 8.0 72 2.0 1.7
24 8.1 7.7 73 2.0 1.7
25 7.8 7.4 74 1.9 1.6
26 7.5 7.1 75 1.9 1.6
27 7.3 6.8 76 1.8 1.5
28 7.0 6.6 77 1.8 1.5
29 6.8 6.3 78 1.8 1.5
30 6.6 6.1 79 1.7 1.4
31 6.3 5.9 80 1.7 1.4
32 6.1 5.7 81 1.6 1.4
33 5.9 5.5 82 1.6 1.3
34 5.7 5.3 83 1.6 1.3
35 5.6 5.1 84 1.5 1.3
36 5.4 4.9 85 1.5 1.2
37 5.2 4.8 86 1.5 1.2
38 5.1 4.6 87 1.4 1.2
39 4.9 4.5 88 1.4 1.1
40 4.8 4.3 89 1.4 1.1
41 4.6 4.2 90 1.3 1.1
42 4.5 4.0 91 1.3 1.1
43 4.4 3.9 92 1.3 1.0
44 4.2 3.8 93 1.2 1.0
45 4.1 3.7 94 1.2 1.0
46 4.0 3.6 95 1.2 1.0
47 3.9 3.5 96 1.2 0.9
48 3.8 3.3
Over 60 Years Old 
c
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Table 3.4: Oxygen-independent rate law-based calculations of ΔS-Cys-
Alb over time at 23 °C for US average age weighted population. a 
a All initial concentrations are based on population averages, the sources of which 
are provided in the main text. Parameters common to all models: k3 = 0.13 M
-1 s-1, 
Ky = 2.0 x 10
-6 M, Kz = 3.5 x 10
-4 M, Cu(II) in plasma = 18.7 x 10-6 M (104), Cu(II) 
in serum = 9.35 x 10-6 M (half of plasma as per main text) 
 
d  [Cys-Cys]0 = 65.4 x 10
-6 M, [Cys]0 = 5 x 10
-6 M, Serum: [AlbSH]0 = 482 x 10
-6 M, 
[SCysAlb]0 = 164 x 10
-6 M, Plasma: [AlbSH]0 = 473 x 10
-6 M, [SCysAlb]0 = 173 x 
10-6 M. [AlbSH]0 and [SCysAlb]0 differ slightly in serum and plasma based on 
results shown in Fig. 3.3. 
Serum Plasma Serum Plasma
Time at Room 
Temperature 
(Hrs)
ΔS-Cys-Alb ΔS-Cys-Alb
Time at Room 
Temperature 
(Hrs)
ΔS-Cys-Alb ΔS-Cys-Alb
0 20.6 20.7 49 2.6 2.3
1 19.3 19.4 50 2.5 2.2
2 18.1 18.1 51 2.5 2.1
3 17.0 17.0 52 2.4 2.1
4 16.0 15.9 53 2.3 2.0
5 15.1 15.0 54 2.3 1.9
6 14.3 14.1 55 2.2 1.9
7 13.5 13.3 56 2.1 1.8
8 12.8 12.6 57 2.1 1.8
9 12.1 11.9 58 2.0 1.7
10 11.5 11.3 59 2.0 1.7
11 10.9 10.7 60 1.9 1.6
12 10.4 10.1 61 1.9 1.6
13 9.9 9.6 62 1.8 1.5
14 9.5 9.1 63 1.8 1.5
15 9.0 8.7 64 1.7 1.4
16 8.6 8.3 65 1.7 1.4
17 8.2 7.9 66 1.6 1.4
18 7.9 7.5 67 1.6 1.3
19 7.6 7.2 68 1.6 1.3
20 7.2 6.9 69 1.5 1.2
21 6.9 6.6 70 1.5 1.2
22 6.7 6.3 71 1.4 1.2
23 6.4 6.0 72 1.4 1.1
24 6.1 5.7 73 1.4 1.1
25 5.9 5.5 74 1.3 1.1
26 5.7 5.3 75 1.3 1.1
27 5.5 5.1 76 1.3 1.0
28 5.3 4.9 77 1.2 1.0
29 5.1 4.7 78 1.2 1.0
30 4.9 4.5 79 1.2 1.0
31 4.7 4.3 80 1.1 0.9
32 4.6 4.1 81 1.1 0.9
33 4.4 4.0 82 1.1 0.9
34 4.2 3.8 83 1.1 0.9
35 4.1 3.7 84 1.0 0.8
36 4.0 3.6 85 1.0 0.8
37 3.8 3.4 86 1.0 0.8
38 3.7 3.3 87 1.0 0.8
39 3.6 3.2 88 0.9 0.8
40 3.5 3.1 89 0.9 0.7
41 3.4 3.0 90 0.9 0.7
42 3.3 2.9 91 0.9 0.7
43 3.2 2.8 92 0.9 0.7
44 3.1 2.7 93 0.8 0.7
45 3.0 2.6 94 0.8 0.6
46 2.9 2.5 95 0.8 0.6
47 2.8 2.4 96 0.8 0.6
48 2.7 2.3
Age-Weighted Population Average d
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CHAPTER 4 
EX VIVO GLYCATION OF HUMAN SERUM ALBUMIN 
4.1 Introduction 
Many of the naturally occurring (bio)chemical reactions in the plasma and serum 
(P/S) compartment of blood are not at equilibrium when blood exits the body (118). In 
addition, exposure of P/S to air results in a dissolved oxygen concentration that is much 
higher than that found in the P/S compartment of blood in vivo. Introduction of this 
relatively high dissolved oxygen concentration into P/S establishes numerous additional 
redox disequilibria that did not exist in vivo.  As such, proper storage and handling 
conditions are critical for maintaining the quality of P/S samples (i.e., maintaining P/S in 
a state that accurately represents blood chemistry in vivo). Exposure to the thawed state 
permits (bio)chemical reactions to run toward equilibrium—a state that, for many 
reactions, does not represent biomolecular status in vivo. The thermodynamic melting of 
ice in plasma commences at -27 °C (119, 120). According to the European 
Pharmacopoeia, plasma is not completely frozen until -30 °C. (46, 99) (The 3 °C 
discrepancy is probably due to the fact that plasma does not exhibit simple eutectic 
behavior) (119, 121). Thus, storage and handling of P/S samples for prolonged periods 
above their melting point of -30 °C may compromise sample integrity, producing 
inaccurate and, in turn, misleading results in clinical research. 
Numerous studies have demonstrated molecular alterations associated with 
inadequate sample handling and storage (14, 24-26, 45, 122). In a recent study, Pasella et 
al. found that plasma samples stored at various temperatures above -30 °C, including       
-20 °C, 4 °C, and room temperature (20-25 °C), showed an apparent variation in the 
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abundance of certain plasma proteins over a two-week period (24). A metabolomics 
study concluded that the concentrations of nearly 20% of the metabolites in serum 
samples are impacted by storage temperature (25).  Another study showed that prolonged 
storage of either whole plasma or isolated plasma DNA had a substantial degradation 
effect on the DNA measured by real-time PCR-based assays (26). Betsou et al. have 
summarized other various biomolecules in P/S that can be altered ex vivo by poor 
handling and storage, ranging from simple ion concentrations to DNA and protein 
concentrations (45).  Clearly, poor storage and handling can affect all types of molecules 
in P/S samples.  
In vivo, P/S proteins undergo glycation through the conjugation of a reducing 
sugar monosaccharide (i.e. glucose) to the protein (usually via a lysine residue side chain) 
(Fig. 1.2). This process proceeds through the formation of a reversible Schiff base and 
later intramolecular rearrangements occur to form a stable, covalently-bonded Amadori 
product, which eventually leads to the formation of advanced glycation end-products 
(123). Protein glycation is an unavoidable process of metabolism in vivo. The degree to 
which it occurs is determined by the concentrations of protein and glucose available in 
P/S and can be measured through various methods, such as glycated hemoglobin 
(HbA1c) measurements, the fructosamine assay (124), or by measuring glycated albumin 
(GA) (125, 126). In vitro, dissolved oxygen has been shown to contribute to a process 
known as autoxidative glycation—a phenomenon that drives protein glycation above and 
beyond that observed in the absence of oxygen and which is likely to be relevant to P/S 
samples ex vivo (23, 127). This ex vivo glycation is similar to that observed in the           
S-Cysteinylation (oxidation) of human serum albumin. 
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In clinical laboratories, P/S storage time is generally kept to a minimum and 
therefore tends not to raise some of the potential integrity issues that can be found in 
research laboratories, where samples may need to be stored indefinitely. Clinicians 
employ HbA1c to gather an overall picture of what average blood sugar levels have been 
over a period of a few months in diabetic patients. Little et al. investigated the stability of 
HbA1c in whole blood samples kept at various storage conditions and determined that 
HbA1c was stable at -70 °C. However, when samples were stored at -20 °C they were 
only stable for 3-57 days, depending on the method of analysis (128). Another clinically 
relevant test to measure blood glucose levels is the fructosamine assay. Fructosamine 
reflects blood glucose levels over the previous 2-3 weeks and may be used to help a 
person with diabetes monitor and control their blood sugar. The fructosamine assay has 
limited clinical usage compared to that of HbA1c; for example, it is not recommended in 
cases where there are significant abnormalities of plasma protein concentrations (e.g., 
nephrotic syndrome, liver cirrhosis) (129). However, like the HbA1c test, storage 
conditions play a role in the stability of fructosamine in P/S. In 1988 a study was 
completed showing that fructosamine in serum is not stable when samples are stored at    
-20 °C for long periods of time (130). Since albumin is the most abundant protein in P/S, 
fructosamine is predominantly a measure of GA—though other circulating proteins such 
as glycated lipoproteins and glycated globulins do contribute to the total concentration of 
fructosamine (131). The concentration of GA can be directly measured by several 
methods, including gel electrophoresis, enzymatic methods, colorimetry, and 
immunoassays (125, 126, 132, 133). HbA1c remains the primary test for protein 
glycation that is used to monitor diabetes; however, studies have shown that GA may be 
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more reliable than HbA1c in certain instances—such as specific clinical conditions in 
which HbA1c does not work properly (e.g., iron deficiency, pregnancy, and end-stage 
renal disease) (134). 
As mentioned above, when P/S samples are drawn from patients they are exposed 
to a dramatic increase in dissolved oxygen concentration. Considering that this spike in 
oxygen concentration may contribute to autoxidative glycation, this creates the potential 
for substantial increases in protein glycation as P/S samples are exposed to the thawed 
state. Previous work has analyzed the effect of storage and handling conditions on ex vivo 
protein oxidation, showing that exposure of P/S to temperatures above -30 °C can have a 
substantial impact on the oxidation status of albumin and apolipoprotein A-I—two of the 
most abundant proteins in P/S (14). The simple dilute-and-shoot LC-MS method used in 
this study provided easily interpreted mass spectra for the relative quantification of all 
intact albumin proteoforms. Here, a simple method to document how albumin glycation 
changes ex vivo under suboptimal storage and handling conditions and evaluate the 
impact of oxidative processes on the ex vivo glycation that takes place within P/S is 
implemented. 
4.2 Materials and Methods 
4.2.1 Materials and Reagents 
Trifluoroacetic acid (TFA; Cat. No. 299537) and formic acid (06440) were 
purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile (L-16923) and HPLC grade 
water (L16978) were purchased from ThermoFisher Scientific (Waltham, MA). Hands-
in-Bag atmospheric chamber (Cat. No. 15552-192) was purchased from VWR. Glucose 
Colorimetric assay kit (Cat. No. 10009582) was purchased from Cayman Chemical. 
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Compressed oxygen and nitrogen were obtained from Arizona State University Stores 
and were 99.999% and 99.99% pure, respectively. 
4.2.2 Plasma and Serum 
For the poorly controlled type 2 diabetic plasma sample involved in the multi-
month time-course study (Fig. 4.1), fasting EDTA blood plasma was collected via 
venipuncture, under IRB approval at the University of Southern California. The sample 
was received frozen on dry ice. To avoid potential acidification of the plasma sample, 
vial headspace was cleared of carbon dioxide prior to thawing for aliquoting (135). Fifty-
microliter aliquots were placed into each of three different types of vials for the long-term 
stability study at -20 °C: a cryogenic storage vial with inner threads and a sealing o-ring, 
a 1.5-mL snap-cap Eppendorf test tube, and a 1.5-mL snap-cap Eppendorf test tube with 
a ~2 mm hole punched in the top.   
Additional matched, fasting EDTA plasma and serum samples were collected 
from several healthy volunteers, via venipuncture, under institutional review board 
approval at Arizona State University. The samples were collected according to the NIH’s 
Early Detection Research Network blood collection standard operating procedures (71, 
72). Within 35 minutes of collection, plasma samples were processed, aliquoted, and 
placed in -80 °C freezer; serum samples were placed at -80 °C within 95 minutes of 
collection. One or more of these P/S specimens were used for all experiments described 
below. Unless otherwise noted, aliquot volumes were 50 µL. 
4.2.3 Measurement of Plasma Glucose Concentration 
Plasma glucose concentrations were measured using the glucose colorimetric 
assay kit from Cayman Chemical (Product No. 10009582), following the standard 
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manufacturer-recommended protocol. A Thermo Scientific Multiskan GO Microplate 
Spectrophotometer was used to record sample absorbance values at 520 nm. 
4.2.4 Incubation under Nitrogen or Oxygen 
P/S samples were incubated in a chamber filled with either nitrogen or oxygen 
using the hand-in-a-bag setup. One sample was removed from the chamber at each time 
point. During removal of the samples from the chamber, a positive pressure was used to 
ensure that no air was able to enter the chamber. No attempt was made to sparge oxygen 
from the P/S samples prior to incubating them under the nitrogen atmosphere. This 
decision was made due to concerns about the overall effectiveness of such a procedure. 
Thus, a limited amount of oxygen must have been dissolved in these samples prior to 
their introduction into the nitrogen chamber.  
4.2.5 Sample Preparation and Analysis 
P/S samples were thawed at room temperature, mixed by vortexing, and then 
centrifuged at 13,000g for 1.5 min to sediment any particulates. 0.5 µL was removed and 
diluted into 500 µL of 0.1% (v/v) trifluoroacetic acid. 5 µL of this solution were injected 
without delay by a Spark Holland Endurance autosampler in microliter pick-up mode and 
loaded by an Eksigent nanoLC*1D at 10 µL/min using 80% water/20% acetonitrile with 
0.1% formic acid onto a protein captrap (Michrom, city/country no longer commercially 
available) configured for unidirectional flow on a six-port diverter valve. The captrap was 
then washed for 3 min with this loading solvent. The flow rate over the protein captrap 
cartridge was then changed to 1 µL/min, and a linear gradient of increasing acetonitrile 
from 20% to 90% was employed to elute the proteins into the mass spectrometer. The 
captrap eluent was directed to a Bruker MicrOTOF-Q (Q-TOF) mass spectrometer 
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operating in positive ion, TOF-only mode, acquiring spectra in the m/z range of 300 to 
3000 with a resolving power of ~20,000 m/Δm full width at half-maximum. Electrospray 
ionization settings for the Agilent G1385A capillary microflow nebulizer ion source were 
as follows: end plate offset -500 V, capillary -4500 V, nebulizer nitrogen 2 bar, and dry 
gas nitrogen 3.0 l/min at 225 °C. Notably, this electrospray ionization mass spectrometer 
has a source design in which the spray needle is kept at ground and the inlet of the 
instrument is brought to a high negative voltage (in positive ion mode). This design is 
important because it avoids the possibility of corona discharge and subsequent artifactual 
protein oxidation (33). Data were acquired in profile mode at a digitizer sampling rate of 
2 GHz. Spectra rate control was by summation at 1 Hz. 
4.2.6 Data Analysis 
As previously described (14), approximately 1 minute of recorded spectra were 
averaged across the chromatographic peak apex of albumin. The electrospray ionization 
charge-state envelope was deconvoluted with Bruker DataAnalysis v3.4 software to a 
mass range of 1000 Da on either side of any identified peak. Deconvoluted spectra were 
baseline subtracted, and all peak heights were calculated, tabulated and exported to a 
spreadsheet for further analysis. Peak heights were used for quantification as opposed to 
peak areas, because of the lack of baseline resolution for some of the peaks. 
Representative raw mass spectra and their corresponding charge deconvoluted forms are 
provided in Figures 4.2 and 4.3. 
Albumin has multiple glycation sites; thus, each molecule of albumin may contain 
multiple glycation states, a maximum of four glycation events per albumin molecule was 
observed—see (Fig. 4.4). The distribution of albumin in each of these four glycation 
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states can readily be determined via electrospray ionization MS. This degree of analytical 
clarity facilitates comprehensive molecular analysis of albumin glycation and is 
expressed here as weighted albumin glycation (WAG). To calculate WAG, the mass 
spectral peak heights of native (unmodified) albumin and of singly, doubly, triply, and 
quadruply glycated albumin are multiplied by 0, 1, 2, 3, and 4 respectively, before 
normalizing by the sum of these peak heights. The glycated and (simultaneously)           
S-cysteinylated albumin proteoform was not considered because at early time points the 
relative abundance of S-cysteinylated albumin is low, making determination of the 
glycated form of this oxidized proteoform difficult to distinguish from baseline noise.  As 
S-cysteinylation increases during P/S exposure to the thawed state (14), glycation of the 
S-cysteinylated form becomes apparent. However, for consistency, only the non-S-
cysteinylated form of albumin was considered in all calculations. Since S-cysteinylation 
does not impact glycation, including information from this proteoform would provide, at 
best, a duplicate measurement of albumin glycation. All statistical analyses were 
conducted with GraphPad Prism 7.  
4.3 Results  
4.3.1 Analytical Reproducibility and Autosampler Stability 
The analysis of intact human albumin by LC-MS for relative quantification of its 
various proteoforms has been previously described (14, 136). However, to verify that this 
approach to measuring albumin glycation is reproducible, intra- and inter-day precision 
of the analytical method were evaluated. Plasma samples from three healthy males and 
three healthy females were analyzed in quadruplicate on three separate days. The average 
WAG in these samples was 14%. The average intra-day precision of WAG (expressed as 
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%CV) was 4.6%, and the total inter-day precision was 6.4%. For the studies described 
herein, samples were injected onto the LC-MS immediately following dilution in 0.1% 
TFA. Nevertheless, it was thought that it might be useful to evaluate the autosampler 
stability of the diluted samples. WAG was found to be stable for at least 1100 minutes   
(~ 18 hrs), which was the time required to run 96 samples (Fig. 4.5). 
4.3.2 Impact of Storage Conditions on Albumin Glycation 
The charge deconvoluted electrospray ionization mass spectra of albumin from a 
healthy fasting donor are shown in Fig. 4.6. The black spectrum represents a fresh, never 
frozen sample in which WAG was 17%. The red spectrum represents an aliquot of the 
same sample stored at -20°C for 60 days, after which time WAG increased to 23%. Raw 
spectra corresponding to the charge deconvoluted spectra shown in Fig. 4.6 are provided 
as Figures 4.2 and 4.3. 
An increasing abundance of glycated albumin in plasma can be seen over time 
when samples are stored at -20°C and at room temperature (25°C)—both in a healthy 
donor and in a poorly controlled type 2 diabetic (pcT2D) patient (HbA1c > 10 and 
triglycerides > 1,000 mg/dL, with a history of coronary artery disease and myocardial 
infarction) (Fig. 4.7A). Both samples were collected and analyzed fresh (i.e., at time 0) 
prior to storage at -20 °C. Free glucose concentrations (± S.D.) in the healthy and pcT2D 
donor were determined in triplicate and found to be 78.8 ± 0.63 mg/dL (4.37 ± 0.035 
mM) and 194 ± 7.3 mg/dL (10.8 ± 0.41 mM), respectively. Analysis of glycated albumin 
at time zero revealed 17% WAG for the healthy donor and 28% WAG for the pcT2D 
donor. Each sample was then aliquoted into three different vial types and stored in a 
manual-defrost freezer at -20 °C; an additional aliquot from the healthy donor was set 
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aside for the room temperature time course. When stored at -20 °C, samples from both 
donors exhibited significant increases in the amount of glycated albumin, reaching 34% 
WAG for the healthy donor and 66% WAG for the pcT2D donor over a time span of 
approximately 200 days (Fig. 4.7A). At room temperature, albumin glycation increased 
within hours, reaching its peak within a week (Fig. 4.7B). Samples stored at -80 °C did 
not show a significant increase in albumin glycation (Fig. 4.7A). 
When the individual data points from the pcT2D sample aliquots stored at -20 °C 
were separated based on the type of vial in which the specimens were stored, a 
statistically significant trend emerged in which the aliquot in the snap-cap test tube 
without a hole exhibited the smallest increase in ex vivo glycation, followed by the 
cryogenic storage vial with inner threads and a sealing o-ring, while the snap-cap test 
tube with a hole punched in the top exhibited the greatest degree of ex vivo glycation 
(Fig. 4.8A; p < 0.01 for all three Wilcoxon matched pairs signed-rank comparisons. A 
Bonferroni correction for multiple comparisons set α at 0.017). These differences 
between storage vials were not as pronounced in the plasma specimen from the healthy 
patient (Fig. 4.8B); in this case the only significant difference observed between the three 
data series was between the aliquots stored in the snap-cap test tube without a hole and in 
the snap-cap test tube with a hole punched in the top (p = 0.0034). 
4.3.3 Matched Plasma vs. Serum 
Matched sets of EDTA plasma and serum were collected from two healthy male 
and two healthy female donors to evaluate potential differences between plasma and 
serum regarding initial measurements of albumin glycation. Plasma and serum samples 
were processed and aliquoted within 35 and 95 minutes of collection, respectively, and 
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then placed in -80 °C freezer until analysis. Average WAG ± S.D. in plasma was 17.7 ± 
0.016; in serum it was 18.0 ± 0.015. A Wilcoxon matched pairs signed-rank test 
comparing plasma vs. serum revealed no significant difference in WAG between the two 
sample types. 
4.3.4 Freeze-Thaw Cycles 
To assess the effect of freeze-thaw cycles on albumin glycation, a plasma sample 
was collected from a healthy donor, measured immediately without ever being frozen    
(n = 6), then split into two separate vials. Both vials were then submitted to 20 freeze-
thaw cycles (going from -80 ºC to room temperature then back to -80 ºC), with one vial 
subjected to opening and closing during each freeze-thaw cycle (to simulate aliquot 
withdrawal) and the other vial remaining sealed during each freeze-thaw cycle. There 
was no significant difference in albumin glycation between the fresh sample and either of 
the freeze-thawed samples. Opening the vials during the freeze-thaw cycles (to simulate 
aliquot withdrawal) did not have a significant effect on albumin glycation (Fig. 4.9). 
4.3.5 Surface Area-to-Volume Effects 
Because oxidation may play a role in ex vivo albumin glycation (23, 137), the 
effects of surface area-to-volume (sa/vol) ratio on albumin glycation were investigated at 
room temperature for up to 25 days by dividing a fresh plasma sample from a healthy 
donor into 100-µL, 200-µL, and 400-µL aliquots in cylindrical, 8-mm internal diameter 
polypropylene screw-cap test tubes. Additional 10-µL aliquots were placed into a 1.5-mL 
conical-bottom polypropylene snap-cap test tube to represent an extreme case of high 
sa/vol. The effect of plasma sa/vol ratio on glycated albumin over time is shown in Fig. 
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4.7. Samples that were stored at a higher sa/vol ratio experienced significantly greater ex 
vivo glycation than those stored at lower sa/vol ratios for the same period. On day 1, the 
only sample that had a significant difference in WAG was the smallest volume of 10 µL 
(i.e., largest sa/vol ratio). For days 3 and 18 there were significant differences between all 
sample volumes. On day 11 there were significant differences between all samples except 
for between 400 and 200 µL. Day 25 there were significant differences between the 10 
µL sample and all other sample volumes (Fig. 4.7A). Significance was determined using 
ANOVA; for all significant differences indicated, Holm-Sidak’s pairwise comparisons p 
< 0.05. As plasma sample sa/vol ratio increases there is an increase in WAG (Fig. 4.7B). 
Plasma albumin glycation for all days was positively correlated to the sample sa/vol ratio 
(Pearson correlation, r ≥ 0.9, p < 0.05). 
4.3.6 Effect of Atmospheric Oxygen 
To investigate the effect of atmospheric oxygen on ex vivo albumin glycation, 
aliquots of plasma from a healthy donor (collected on a different day than the other 
samples employed in this study) were incubated under nitrogen or oxygen for 16 days.  
For nearly all time points, the samples incubated under oxygen exhibited higher levels of 
WAG than the samples incubated under nitrogen (Fig. 4.10). After propagating the error 
for all measurements (138) the average difference between all nitrogen and oxygen data 
points past time zero was found to be 0.022 ± 0.005 WAG units, which was significantly 
different from zero (Wilcoxon matched pairs signed-rank test; p = 0.016). As a control 
experiment, data were also collected from samples kept in air; these data points largely 
fell in between those of the nitrogen and oxygen data points (Fig. 4.10).  
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4.4 Discussion 
Although plasma and serum samples may appear to be frozen at -20 °C, they are 
not fully frozen or chemically inactive at this temperature. Previously, it has been 
demonstrated that protein oxidation occurs slowly but inevitably when P/S samples are 
stored at -20 °C (14). Herein it is shown that glycation of albumin in blood plasma of 
both healthy and diabetic donors increases substantially over time at temperatures at or 
above the known plasma freezing point of -30°C (46, 99, 119, 120).  It is important to 
note that when samples were stored at -80 °C there was no significant alteration of WAG 
ex vivo (Fig. 4.1A). This is consistent with the stability of protein glycation observed in 
other studies (139-141) as well as the stability shown for protein oxidation (14). 
Samples shown in Figure 4.1 were collected fresh, at which point WAG in the 
healthy donor was 17% and WAG in the pcT2D donor was 28%. This difference in initial 
WAG values was expected based on the higher average concentration of blood glucose 
that is observed in T2D patients (142, 143) and reported above. Both samples 
experienced an ex vivo increase in albumin glycation: Over a time period of 268 days 
at -20 °C, the sample from the healthy donor increased to 34% WAG (a relative increase 
of 100%, Fig. 4.1A). After 229 days, the sample from the pcT2D donor increased to 66% 
(a relative increase of 136%, Fig. 4.1A). The large difference in the absolute increase in 
percent WAG can be explained by the fact that fasting plasma glucose in the pcT2D 
patient was nearly 2.5 times the concentration found in the healthy donor. 
Watano et al. showed that GA in diabetics experienced a relative increase of 17% 
after 6 months and 73% after 12 months when serum was stored at -20 °C (141). The 
albumin-specific enzymatic method employed by Watano et al. accounts for multiple 
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glycation events per albumin molecule and is thus similar to our WAG metric. 
Differences in the relative increases in glycated albumin between our study and the 
Watano study might be accounted for by the concentration of free glucose in the samples 
when drawn, but these were not reported by Watano et al. (141). Notably, Watano et al. 
observed the greatest increases in GA between 6 and 12 months of their 12-month study, 
but the greatest increases in WAG in our study occurred within the first 6 months (Fig. 
4.1A). The reason for this discrepancy in the kinetic profiles is unknown. 
Though numerous groups have evaluated the stability of protein glycation ex vivo 
(139-141), the mechanism(s) behind observed increases in protein glycation in P/S have 
not been elucidated.  Ex vivo increases in protein glycation are likely due to either of two 
mechanisms: First, the chemical reaction between glucose and protein may not be at 
chemical equilibrium in vivo. This mechanism is most likely to be relevant to proteins 
with short half-lives, albumin has a half-life of about 20 days (144). At 37 °C the rate 
constant for the overall rate-limiting formation of the Amadori product from the Schiff 
based intermediate is 0.026 hr-1 (145). As a first-order reaction, the half-life for the Schiff 
base intermediate is given by the equation t1/2 = ln 2/k and is therefore 26.7 hrs. Thus, the 
reaction can effectively be considered to be at equilibrium within one week—a time 
period well within the ~ 20-day half-life of albumin. Considered in conjunction with the 
fact that blood samples were drawn from fasting subjects, it is rather unlikely that the 
increase in albumin glycation observed ex vivo is simply due to chemical equilibration. 
A second possible mechanism behind the ex vivo increase in albumin glycation is 
autoxidative glycation (23, 127). When P/S is exposed to air it takes on a dissolved 
oxygen concentration as high as 0.25 mM (88, 89)—a concentration far higher than that 
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found in vivo where oxygen in the blood is carried by hemoglobin inside of red blood 
cells. To begin to ascertain the role of oxidative processes in the ex vivo glycation of 
albumin in P/S, samples were incubated for several days under atmospheres of nitrogen 
or oxygen (Fig. 4.10). Starting at 18 hours glycation was, on average, elevated under an 
oxygen atmosphere relative to a nitrogen atmosphere. These results suggest that the 
mechanism underlying the ex vivo increase in albumin glycation involves molecular 
oxygen—a finding that is further substantiated by the facts that 1) increased plasma 
surface area-to-volume ratios enhanced the rate of ex vivo glycation (Fig. 4.7) and 2) 
plasma storage at -20 °C in vials with holes in them resulted in significantly greater ex 
vivo glycation than when the same sample was stored in vials without holes (Fig. 4.8).  
The precise molecular mechanism of autoxidative glycation is not yet clear.  In 
1987 Wolff et al. first reported roles for transition metals and oxygen in the autoxidation 
of glucose (23)—a phenomenon that accounted for up to 45% of the covalent attachment 
of glucose to bovine serum albumin when the two components were incubated together in 
air. They postulated that the two-electron oxidation of glucose mediated by transition 
metals and molecular oxygen produced glucosone, an α-dicarbonyl derivative of glucose 
that readily reacts with protein amino groups. However, in 1995 Wells-Knecht and 
colleagues demonstrated that only arabinose and glyoxal (but not glucosone) are 
produced during the autoxidation of glucose, neither of which would result in a 162 Da 
mass shift upon attachment to a protein molecule. Moreover, they demonstrated that 
glucosone is not even an intermediate in the formation of arabinose or glyoxal during the 
oxidative degradation of glucose (137). This being the case, the only way to reconcile the 
findings of these two groups with the findings that a 162-Da molecule attaches to 
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albumin during exposure of P/S to thawed conditions is to propose that the enediol 
radical anion of glucose that has been postulated to form upon initial one-electron 
oxidation (23) reacts directly with albumin (rather than a molecule of oxygen or a 
transition metal atom, which facilitates the second-electron oxidation of glucose in the 
Wolff mechanism (23)) (Fig. 4.11). Considering that the total concentration of free 
transition metals in P/S is in the low micromolar range and that the concentration of 
oxygen in P/S is, at maximum, approximately 0.25 mM (88, 89) but the concentration of 
albumin is higher—at approximately 0.65 mM (146) (putting the total number of reactive 
amino-group equivalents with albumin in the millimolar range), this mechanism for the 
oxidative ex vivo glycation of albumin in P/S may be viable—though it has yet to be 
proven.        
4.5 Conclusion 
In conclusion, this study demonstrated that albumin glycation increases 
substantially ex vivo when fasting P/S specimens from either healthy subjects or diabetics 
are stored at -20 °C or otherwise subjected to temperatures above their melting point 
of -30 °C. The mass spectra employed to quantify albumin glycation revealed the 
presence of multiple glycation events per albumin molecule (Fig. 4.4), affording the 
opportunity to account for these events in a metric referred to here as weighted albumin 
glycation. Furthermore, experiments conducted under atmospheres of nitrogen vs. oxygen 
in conjunction with studies on the impact of P/S surface area-to-volume ratio strongly 
suggested a role for autoxidative processes during the ex vivo glycation of albumin in 
human P/S.  
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Figures 
Figure 4.1: WAG in plasma over time at -80°C and -20°C (manual defrost freezers) 
(A), and at room temperature (25°C) (B). One sample was collected from a healthy 
donor and a second sample was obtained from a poorly controlled type 2 diabetic 
(pcT2D) with an HbA1c greater than 10 and a history of coronary artery disease and 
myocardial infarction. Both samples were collected and analyzed fresh, starting on 
Day 0—at which time WAG in the healthy and pcT2D samples was 17% and 28%, 
respectively. At -20°C albumin glycation nearly doubled in both the healthy and 
pcT2D samples after about 200 days. Samples stored at -80°C did not show an 
increase in WAG. Shown is the mean ± S.D. of the three aliquots per point.               
(* Indicates a significant difference from the initial time point; Repeated measures 
ANOVA, p < 0.0001 for all Tukey pairwise comparisons). An additional aliquot from 
the healthy donor was set aside for the room temperature time course. At room 
temperature (B), albumin glycation increased within hours, reaching its peak within 
two weeks. 
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Figure 4.2: Raw (top), baseline subtracted (middle), and charge deconvoluted mass 
spectra (bottom) of a fresh never frozen plasma sample. 
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Figure 4.3: Raw (top), baseline subtracted (middle), and charge deconvoluted mass 
spectra (bottom) of the same sample as in Fig. 4.2 but has been stored for 60 days at   
-20 °C.  
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Figure 4.4: Each molecule of albumin may contain multiple glycation states a 
maximum of four glycation events per albumin molecule was observed in the pcT2D 
samples. 
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Figure 4.5: Weighted albumin glycation measurements were stable for at least 18 
hours when pre-diluted samples were placed on an autosampler held at 8 ºC. 
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Figure 4.6: Charge deconvoluted electrospray ionization mass spectra of albumin 
from a healthy donor showing an increase in glycated albumin under less-than-ideal 
storage conditions.  The black spectrum is from a fresh, never frozen sample. The red 
spectrum is from the same sample stored at -20 °C for 60 days. 
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Figure 4.7: Effect of surface area-to-volume ratio on the ex vivo increase in plasma 
albumin glycation at room temperature. WAG in plasma samples of different volumes 
over time at room temperature (A), each of which had a different surface area-to-
volume ratio (B). Bar graphs represent the average of duplicate analyses with the error 
bars representing the actual points. On day 1 there was a significant difference 
between the 10 µL sample and all other samples.  On day 3 and 18 there was a 
significant difference between all volumes (i.e., surface area-to-volume ratios). For 
day 11, there was a significant difference between all volumes except 400 and 200 µL. 
On day 25 there was a significant difference between the 10 µL sample and all other 
sample volumes. (* Represents a significant difference between surface area-to-
volume ratios as determined by ANOVA; p < 0.05 for all Holm-Sidak’s pairwise 
comparisons. “NS” indicates that the bracketed samples were not significantly 
different.). Individual data points are shown in the scatter plot (B).  In this plot, the 
sample with the highest sa/vol ratio corresponds to the lowest-volume sample (10 µL) 
shown in (A); accordingly, sa/vol ratios decrease (B) as volume increases (A).  For all 
days sa/vol ratios were positively correlated with albumin glycation (Pearson 
Correlation, r ≥ 0.9, p < 0.05). 
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Figure 4.8: Weighted albumin glycation over time in samples stored at -20 °C in 
different vial types. These data are the same as those shown in Fig. 3 for the pcT2D 
sample (A) and the healthy donor sample (B), but expanded in detail based on the vial 
type in which each of the 3 aliquots per patient were stored. (In Fig. 3 each of the 
three vial types was considered a replicate sample.) For the pcT2D plasma sample (A) 
statistically significant differences were observed between all 3 vial types (p < 0.01 
for all three Wilcoxon matched pairs signed-rank comparisons. A Bonferroni 
correction for multiple comparisons set α at 0.017). The differences between storage 
vials were not as pronounced in the plasma specimen from the healthy patient (B); in 
this case the only significant difference observed between the three data series was 
between the aliquots stored in the snap-cap test tube without a hole and in the snap-
cap test tube with a hole punched in the top (p = 0.0034). 
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Figure 4.9: Effect of freeze-thaw cycles on weighted albumin glycation. Following 
initial analysis (n = 6 technical replicates), a fresh plasma sample from a healthy 
donor was split into two cryogenic storage vials, each of which was subjected to 20 
freeze-thaw cycles prior to analysis in triplicate (mean ± S.D. shown). One vial was 
opened at each thaw cycle, and the other vial was not opened until 20 freeze-thaw 
cycles were completed. There was no significant difference between the fresh and 
incubated samples (Repeated measures ANOVA, p = 0.66). 
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Figure 4.10: Role of atmospheric oxygen on the ex vivo glycation of albumin in blood 
plasma. WAG in healthy-donor plasma kept under pure nitrogen, pure oxygen or air at 
room temperature (n = 3 aliquots measured per data point). Significant differences 
were observed between the nitrogen and oxygen series (p = 0.016) and the nitrogen 
and air series (p = 0.008), but not between the air and oxygen series (Wilcoxon 
matched pairs signed-rank test; a Bonferroni correction for multiple comparisons set α 
at 0.017 instead of 0.05). 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Collection, processing, storage and handling expose biospecimens to pre-
analytical variables that have the potential to produce misleading results in downstream 
clinical research. Most investigators know that P/S should be stored at -80 °C. As it is 
clearly demonstrated here, simply accepting that SOPs were followed (with or without a 
detailed paper trail as evidence) or just simply accepting that specimens were stored at     
-80 °C after initial collection and processing, represents a naïve approach to clinical 
research.  
The rate law for the ex vivo formation of S-Cys-Alb at room temperature has been 
determined. And with the simple, low-consumption, ΔS-Cys-Alb assay, it is now 
relatively quick and easy to identify archived samples that are not suitable for a particular 
study. With the proper implementation of this ΔS-Cys-Alb assay, in connection with the 
determined rate law, research studies that use improperly stored and handled P/S samples 
will become a thing of the past.  
Efforts are underway to develop a comprehensive rate law-based model that 
considers oxygen and all relevant metals (e.g., copper and iron) within their P/S-liganded 
context across the range of temperatures likely to be encountered by P/S samples (e.g.,    
4 °C and -20 °C). While the first critical steps in this direction have been taken, 
establishing a fully comprehensive rate law will facilitate the most accurate possible 
linkage of ΔS-Cys-Alb to the stability of clinically important analytes in P/S, merely by 
defining the stability limitations of the clinical analytes themselves. That is, if proper 
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analytical assay development guidelines are followed and stability studies are conducted 
on P/S samples during clinical marker assay development, then every clinical analyte will 
automatically be linked to ΔS-Cys-Alb by virtue of the ΔS-Cys-Alb rate law. This 
represents a far more efficient approach to establishing a global marker of P/S integrity 
than any in which an integrity marker is simply empirically measured in parallel with the 
clinical marker in order to establish a linkage between the two.      
For clinical research that employs archived P/S samples, the quality of samples 
should be of primary concern. While no widely accepted gold standard marker of P/S 
integrity has been established, this work represents an important step in that direction.  
The research presented here provides a robust, mechanistically understood tool to assess 
the integrity of the already innumerable pre-existing P/S specimens—and thus contribute 
substantially to decrease the large number of false leads produced in biomarker research. 
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APPENDIX A 
ILLUSTRATED MODELS OF ALBUMIN OXIDATION 
  
  123 
Kinetics simulations in which the Reaction 2 (see Section 2.3.1.1) rate law 
constants k3, Ky and Kz are individually changed to their 37 °C values or 10x below these 
values. a-b) Serum and plasma, respectively, where k3 = 0.32 M
-1 s-1, the value 
established by Kachur et al. (20) at 37 °C; c-d) k3 = 0.032 M
-1 s-1; e-f) Ky = 5.1 x 10
-6 M, 
the value established by Kachur et al. (20) at 37 °C; g-h) Ky = 5.1 x 10
-7 M; i-j) Kz = 8.8 x 
10-4 M, the value established by Kachur et al. (20) at 37 °C; k-l) Kz = 8.8 x 10
-5 M. Cys-
Cys is abbreviated as CSSC in the legends. 
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APPENDIX B 
HYPOTHETICAL KINETIC MODEL AND SIMULATIONS THAT CONSIDER 
OXYGEN AS RATE LIMITING 
  
  131 
Part A) Chemical and mathematical equations. Reactions 10 and 11 break apart 
Reaction 2 (see Section 2.3.1.1) to show how O2(aq) recycles Cu(I) into Cu(II) and allows 
Cu(II) to serve as the reaction catalyst. The rate law described by Kachur et al. (20) for 
Reaction 2 omits O2 (i.e., assumes it is not rate limiting) and takes into account the 
equilibrium binding affinities for the first and second Cys liganding to Cu(II). Thus, 
strictly speaking, it is actually the rate law for Reaction 10—but one in which the Cu(I) 
produced is assumed to be immediately recycled back to Cu(II). When O2(aq) is in short 
supply, Reaction 11 can become rate limiting and must be taken into account in the 
model.  
Taking O2(aq) into account requires three additional differential equations 
(Equations 12-14), two additional reaction components (O2(aq) and Cu(I)) and two 
additional rate constants (k4 and 𝑘𝑂2). Simulations based on this model (Part b) should be 
considered speculative because not all parameters are known: O2(aq) was estimated at 30% 
saturation (70 µM) and Cu(I) was assumed to initially exist only in trace quantities (i.e., < 
1% of total Cu or 0.1 µM). k4 will vary depending on how Cu(II) is bound in P/S. A value 
of 200 M-1 s-1 was employed based on the known rate constant for the reaction of O2(aq) 
with the Fe(II)-EDTA complex (147) (that for the Cu(I)-EDTA complex is unknown). 
𝑘𝑂2  is a constant that describes the rate at which O2(g) from the headspace above the P/S 
sample dissolves, becoming how O2(aq). It was estimated at 1 x 10
-10 M/s. 
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 Part B) Model predictions (lines), overlaid on actual results (symbols), that take 
into account best estimates for the additional parameters (reaction components and rate 
constants) required for an O2(aq)–dependent model as described in the preceding 
paragraph (panels a-b, corresponding to serum and K2EDTA plasma, respectively). All 
other parameters in the model exist as described in Fig. 2.5. Additional panels vary the 
starting concentration of one reaction component or one rate constant at a time (generally 
-10x or +10x unless physically unreasonable) to evaluate its effect on the model. c-d) 
Starting O2(aq) = 250 µM (saturation); e-f) Starting O2(aq) = 7 µM; g-h) k4 = 2,000 M
-1 s-1 ; 
i-j) k4 = 20 M
-1 s-1 ; k-l) 𝑘𝑂2  = 1 x 10
-9 M/s; m-n) 𝑘𝑂2 = 1 x 10
-11 M/s (This simulates 
placing P/S into a nitrogen (low O2(g)) atmosphere following initial processing (which 
permits an modest initial concentration of O2(aq) to develop in the sample—i.e., ~ 70 µM). 
The trajectory difference between the predicted and observed formation of S-Cys-Alb 
matches, approximately, the difference between the unfortified plasma sample incubated 
under N2 and the one incubated under air in Fig. 2.7). Cys-Cys is abbreviated as CSSC in 
the legends. 
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